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The	   glycosylphosphatidylinositol	   (GPI)-­‐anchored	   Prion	   Protein	   (PrPC)	   is	  
known	   for	   mediating	   neurotrophic	   actions	   after	   binding	   to	   the	   Stress	  
Induced	  Protein	  1	  (STI1).	  STI1	  induces	  neuronal	  survival	  through	  Ca2+	  influx	  
via	   the	   PrPC-­‐alpha	   7	   nicotinic	   acetylcholine	   receptor	   (α7nAChR)	   complex.	  
Recently,	  PrPC	  was	  found	  to	  be	  a	  receptor	  for	  beta-­‐amyloid	  oligomers	  (Aβ)	  
and	  a	  mediator	  of	  Aβ	  neurotoxicity.	  We	  hypothesized	   that	  STI1	  promotes	  
neuronal	  survival	  against	  the	  neurotoxicity	  of	  Aβ.	  A	  Ca2+	  signaling	  assay	  was	  
used	  to	  test	  the	  STI1	  and	  Aβ	  dependence	  on	  the	  PrPC-­‐α7nAChR	  complex	  for	  
Ca2+	   influx.	  Cell	  death	  assays	  were	  performed	   to	  assess	   the	  STI1	  ability	   to	  
protect	   against	   Aβ-­‐induced	   neurotoxicity	   on	   embryonic	   hippocampal	  
neurons.	   Aβ	   induced	   sustained	   Ca2+	   influx	   in	   a	   PrPC	   and	   α7nAChR	  
dependent	   way.	   Aβ-­‐induced	   neuronal	   death	   was	   dependent	   on	   the	  
presence	   of	   PrPC.	   STI1	   rescued	   neurons	   against	   Aβ-­‐induced	   neurotoxicity.	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The	   number	   of	   Alzheimer’s	   disease	   (AD)	   patients	   worldwide	   is	   increasing	   every	   year	  
with	   projections	   reaching	   65	   million	   AD	   patients	   worldwide	   by	   2030	  
(www.alzforum.org).	  The	  risk	  of	  developing	  AD	  increases	  with	  age	  and	  is	  of	  concern	   in	  
Canada	  since	  the	  population	  of	  Canada	  is	  aging.	  Canada’s	  senior	  population,	  individuals	  
over	  the	  age	  of	  65,	  has	  grown	  to	  2.1%	  by	  2011	  and	  is	  projected	  to	  reach	  14.1%	  of	  the	  
overall	  Canadian	  population	  (www.hc-­‐sc.gc.ca).	  Although	  age	  is	  the	  strongest	  risk	  factor	  
for	  the	  most	  common	  type	  of	  dementia,	  AD,	  the	  natural	  aging	  process	  does	  not	  include	  
the	   pathology	   observed	   in	   AD.	  With	   the	   continuous	   aging	   of	   a	   population,	   especially	  
with	  increasing	  life	  expectancy,	  a	  solution	  needs	  to	  be	  found	  for	  AD.	  Currently,	  there	  is	  
no	  way	  to	  prevent	  AD.	  As	  a	  result,	  there	  is	  considerable	  hope	  that	  research	  in	  the	  field	  
of	  AD	  will	  produce	  preventative	  measures	  that	  cut	  the	  incidence	  rate	  of	  AD	  and	  alleviate	  
the	  economic	  and	  social	  burdens	  of	  AD	  in	  Canada.	  
1	   	   Background	  
1.1	   Alzheimer’s	  disease	  	  
AD	  is	  a	  progressive	  terminal	  disease	  that	  results	   in	  the	  degeneration	  of	  brain	  neurons.	  
The	   two	  types	  of	  AD	  are	   i)	  early-­‐onset	  AD,	  also	  known	  as	  Familial	  AD,	  with	  symptoms	  
appearing	  before	  the	  age	  of	  60,	  and	  ii)	  late-­‐onset	  AD,	  also	  known	  as	  Sporadic	  AD,	  with	  
symptoms	  appearing	  after	   the	  age	  of	  60.	   Symptoms	  of	  AD	   include;	   lack	  of	   short-­‐term	  
memory,	   compromised	   decision-­‐making,	   and	   communication	   difficulties	   (Braak,	   Del	  





Tredici,	   Schultz,	   &	   Braak,	   2000;	   Braak,	   Rub,	   Schultz,	   &	   Del	   Tredici,	   2006;	   Minati,	  
Edginton,	   Bruzzone,	   &	   Giaccone,	   2009;	   Morris	   &	   Price,	   2001;	   Selkoe,	   2001;	  Walsh	   &	  
Selkoe,	   2004).	   AD	   postmortem	   brains	   are	   characterized	   by	   general	   brain	   atrophy,	  
ventricular	  enlargement,	  and	  accumulation	  of	  different	  protein	  aggregations	  (DeLegge	  &	  
Smoke,	  2008;	  Zipp	  &	  Aktas,	  2006).	  
1.1.1 Current	  Treatment	  Approach	  	  
	  The	  majority	   of	  medications	   and	  most	   AD	   clinical	   research	   is	   focused	   on	   delaying	   or	  
preventing	   the	   symptoms	   of	   AD,	   but	   not	   on	   preventing	   the	   disease.	   Drugs	   currently	  
used	   to	   treat	   AD	   are	   either	   acetylcholinesterase	   (AChE)	   inhibitors	   or	   N-­‐methyl-­‐D-­‐
aspartate	   receptor	   (NMDAR)	   antagonists.	   Cholinergic	   tone	   is	   disrupted	   in	   AD	   patients	  
due	  to	  a	  decrease	  in	  the	  level	  of	  acetylcholine	  (Ach)	  at	  the	  synapse	  (Lahiri,	  Rogers,	  Greig,	  
&	   Sambamurti,	   2004).	   The	   first	   line	   of	   drugs	   used	   to	   treat	   AD	   patients	   is	   the	   AChE	  
inhibitors.	   AChE	   inhibitors	   increase	   the	   level	   of	   Ach	   at	   the	   synapse	   resulting	   in	  
enhancement	  of	  cholinergic	   tone	  (Whitehouse,	  1998).	  AChE	   inhibitors	  are	  widely	  used	  
in	  treating	  the	  symptoms	  of	  AD.	  	  
Excessive	   release	   of	   the	   excitatory	   neurotransmitter	   glutamate	   can	   result	   in	   neuronal	  
death,	   due	   to	   NMDA	   receptor	   mediated	   excitotoxicity.	   Memantine,	   an	   NMDAR	  
antagonist,	  is	  administered	  for	  the	  treatment	  of	  moderate-­‐to-­‐severe	  AD	  since	  glutamate	  
excitotoxicity	   and	   neuronal	   degeneration	   are	   characteristic	   of	   later	   stages	   of	   AD	  





(Hyman,	   2011).	   However,	   neither	   AChE	   inhibitors	   nor	   Memantine	   can	   prevent	   the	  
progression	   of	   AD	   (Schmitt,	   Bernhardt,	   Moeller,	   Heuser,	   &	   Frolich,	   2004).	   Therefore,	  
current	  treatment	  is	  focused	  on	  alleviating	  the	  symptoms	  of	  AD,	  but	  not	  on	  dealing	  with	  
the	  proposed	  causes	  of	  AD,	  such	  as	  the	  accumulation	  of	  amyloid-­‐β	  (Aβ).	  	  	  
	  
1.1.2 Amyloid	  Cascade	  Hypothesis	  	  
Research	  conducted	  on	  AD	  is	  mainly	  driven	  by	  clinical	  observations	  made	  in	  the	  AD	  field.	  
Some	  of	  the	  original	  discoveries	  in	  AD	  include	  the	  identification	  of	  insoluble	  aggregates	  
of	  Aβ	  (Lesne	  et	  al.,	  2006),	  found	  in	  senile	  plaques	  (SPs);	  and	  the	  discovery	  of	  intracellular	  
filaments	   of	   hyperphosphorylated	   tau	   protein,	   named	   neurofibrilary	   tangles	   (NFTs)	  
(Alzheimer,	   Stelzmann,	   Schnitzlein,	   &	   Murtagh,	   1995).	   Although	   SPs	   and	   NFTs	   were	  
found	   to	  be	   reliable	  as	  diagnostic	   tools	   for	  AD	   in	  postmortem	  brains	   (Newell,	  Hyman,	  
Growdon,	  &	  Hedley-­‐Whyte,	  1999),	  SPs	  and	  NFTs	  do	  not	  accurately	  predict	  the	  severity	  
of	  AD	  (Katzman	  et	  al.,	  1988).	  Alternatively,	  SPs	  and	  NFTs	  are	  considered	  final	  molecular	  
reservoirs	  of	  the	  active	  toxic	  species,	  the	  quantity	  of	  which	  could	  be	  more	  predictive	  of	  
the	  progress	  of	  AD.	  	  	  	  
Genetic	   variations	   in	   the	   genes	   of	   the	   Amyloid	   Precursor	   Protein	   (APP)	   (Goate	   et	   al.,	  
1991;	  Mullan	   et	   al.,	   1992)	   and	   enzymes	   involved	   in	   the	   cleavage	   of	   APP	   (γ-­‐secretase	  
complex)	  may	  be	  involved	  in	  the	  pathophysiology	  of	  AD.	  Mutations	  in	  these	  genes	  can	  





result	   in	  accumulation	  of	  Aβ	  peptide	   (Goate	  et	  al.,	   1991;	   Levy-­‐Lahad	  et	  al.,	   1995)	  and	  
increasing	   the	  occurrence	  of	   familial	   AD	   (Levy-­‐Lahad	  et	   al.,	   1995).	   In	   addition,	   certain	  
alleles	   of	   Apolipoprotein	   E	   (Castellano	   et	   al.,	   2011;	   Deane	   et	   al.,	   2008),	   a	   protein	  
involved	   in	  the	  clearance	  of	  Aβ	  peptides,	  have	  been	  correlated	  to	  the	   incidence	  of	  AD	  
(Mahley,	  Weisgraber,	  &	  Huang,	  2006;	  Strittmatter	  et	  al.,	  1993).	  The	  discoveries	  of	   the	  
insoluble	  SPs	  and	   the	  NFTs	   from	  analysis	  of	  postmortem	  brains,	   and	   the	  genetic	   tests	  
that	  identified	  the	  factors	  involved	  in	  the	  production	  and	  accumulation	  of	  Aβ	  reinforce	  
the	  original	  Amyloid	  Cascade	  (AC)	  hypothesis	  (J.	  A.	  Hardy	  &	  Higgins,	  1992;	  Selkoe,	  1991).	  	  
According	   to	   the	   AC	   hypothesis,	   the	   origin	   of	   AD	   pathogenesis	   is	   Aβ	   production,	   Aβ	  
accumulation	  (Goate	  et	  al.,	  1991;	  Levy-­‐Lahad	  et	  al.,	  1995)	  and	  intracellular	  deposition	  of	  
NFT	  (Bondareff,	  Mountjoy,	  Roth,	  &	  Hauser,	  1989;	  Grundke-­‐Iqbal	  et	  al.,	  1986;	  Santacruz	  
et	   al.,	   2005).	   The	   etiology	   of	   dementia	   according	   to	   the	   AC	   hypothesis	   is	   Aβ-­‐induced	  
neuronal	  dysfunction	  and	  death.	  Nonetheless,	  the	  original	  AC	  hypothesis,	  proposed	  by	  
Drs.	  Hardy	  and	  Higgins	  in	  1992	  (J.	  A.	  Hardy	  &	  Higgins,	  1992),	  attributes	  the	  symptoms	  of	  
AD	   to	   the	  pathology	   caused	  by	   the	   insoluble	  depositions	  of	  Aβ	  peptides.	   Interestingly	  
however,	  the	  accumulation	  of	  soluble	  Aβ	  oligomeric	  species	  correlates	  better	  with	  the	  
progress	  of	   the	  disease	   than	  accumulation	  of	   insoluble	  plaques	   (McLean	  et	  al.,	   1999).	  
Therefore,	  recent	   literature	  focuses	  on	  how	  Aβ	   is	  produced,	  why	  Aβ	  accumulates,	  and	  
the	  molecular	  mechanisms	   utilized	   by	   the	   soluble	  mobile	   Aβ	   to	   induce	   neurotoxicity.	  
Consequently,	   the	   reduction	   in	   Aβ	   generation	   and	   the	   enhancement	   of	   its	   clearance	  





have	  become	  one	  of	  the	  therapeutic	  approaches	  currently	  studied	  (Reitz,	  2012).	  These	  
trials	   rely	   on	   a	   body	   of	   evidence	   linking	   the	   neurotoxicity	   of	   soluble	   Aβ	   to	   deficits	   in	  
synaptic	  plasticity.	  Indeed,	  impairment	  of	  synaptic	  plasticity	  and	  deformation	  of	  synaptic	  
structure	  correlate	  better	  with	  the	  progress	  of	  AD	  (Terry	  et	  al.,	  1991)	  and	  occur	  prior	  to	  
formation	  of	  Aβ	  deposits	  in	  AD	  transgenic	  mouse	  models	  (Hsia	  et	  al.,	  1999;	  Lambert	  et	  
al.,	   1998).	   It	   is	   known	   that	   very	   small	   concentrations	   of	   Aβ	   oligomers	   can	   result	   in	  
inhibition	  of	  long-­‐term	  potentiation	  (LTP)	  (Cullen,	  Suh,	  Anwyl,	  &	  Rowan,	  1997;	  Lambert	  
et	  al.,	  1998),	  the	  cellular	  correlate	  of	  learning	  and	  memory.	  Furthermore,	  Aβ	  oligomers	  
were	  found	  to	  induce	  major	  cognitive	  dysfunction	  when	  infused	  in	  the	  CNS	  (Cleary	  et	  al.,	  
2005;	  Lesne	  et	  al.,	  2006).	  Together,	  these	  results	  emphasize	  the	  synaptotoxic	  effects	  of	  
Aβ	  oligomers.	  	  	  
Although	   the	   AC	   hypothesis	   provides	   general	   links	   that	   aid	   in	   understanding	   the	  
pathology	  of	  AD	  and	  the	  symptoms	  of	  dementia,	  it	  provides	  no	  molecular	  explanation	  of	  
how	  Aβ	  can	  alter	  physiological	  signaling	  pathways	  leading	  to	  neuronal	  dysfunction	  and	  
disruption	   of	   synaptic	   transmission.	   Thus,	   many	   hypotheses	   stemming	   from	   the	   AC	  
hypothesis	  are	  aimed	  at	  understanding	  how	  soluble	  Aβ	  oligomers	  can	  disturb	  synaptic	  
plasticity	   and	   cellular	   processes	   leading	   to	   neuronal	   dysfunction,	   stress,	   and	   death.	  
There	  are	  many	  hypothesized	  Aβ-­‐driven	  mechanisms	  that	  can	  be	  included	  in	  the	  cellular	  
pathogenic	   cascade	  of	   the	  AC	  hypothesis.	   Some	  of	   the	  molecular	  mechanisms	   include	  
involvement	  of	  NMDA	  receptors	  (J.	  Hardy	  &	  Selkoe,	  2002;	  Hsia	  et	  al.,	  1999;	  Kamenetz	  et	  





al.,	   2003;	   Klein,	   2002;	   Lambert	   et	   al.,	   1998;	  Walsh	   &	   Selkoe,	   2004),	   AMPA	   receptors	  
(Chang	  et	  al.,	  2006;	  Hsieh	  et	  al.,	  2006;	   Ikonomovic	  et	  al.,	  1997;	  Parameshwaran	  et	  al.,	  
2007),	   mGlu	   receptors	   (Chin,	  Ma,	  MacTavish,	   &	   Jhamandas,	   2007;	   Ikonomovic	   et	   al.,	  
1997),	  and	  Post	  Synaptic	  Density	   (PSD)	  proteins	  (Kim	  &	  Sheng,	  2004).	  Additionally	  and	  
more	   importantly	   to	   the	   present	   study,	   Aβ	   has	   been	   shown	   to	   utilize	   the	   alpha7	  
nicotinic	   acetylcholine	   receptor	   (α7nAChR)	   and	   the	   cellular	   Prion	   Protein	   (PrPC)	   on	  
neurons	  as	  putative	   receptors	   to	   cause	  pathogenesis	   (Chen,	   Yadav,	  &	  Surewicz,	   2010;	  
Chung	   et	   al.,	   2010;	   Dineley,	   Bell,	   Bui,	   &	   Sweatt,	   2002;	   Dineley	   et	   al.,	   2001;	   Lauren,	  
Gimbel,	   Nygaard,	   Gilbert,	   &	   Strittmatter,	   2009;	   Nygaard	   &	   Strittmatter,	   2009;	  Wang,	  
Lee,	  Davis,	  &	  Shank,	  2000;	  Wang,	  Li,	  Benedetti,	  &	  Lee,	  2003).	  
α7nAChRs	  and	  AD	  	  
1.1.3 α7	  Nicotinic	  Acetylcholine	  Receptor	  	  
Nicotinic	  acetylcholine	   receptors	  consist	  of	   several	   classes.	  One	  of	   these	  classes	   is	   the	  
homomeric	   α7.	   Nicotinic	   receptors	   consist	   of	   variable	   combinations	   of	   subunits	  
arranged	  in	  a	  basic	  pentameric	  structure,	  which	  forms	  an	  ion	  pore	  (Sargent,	  1993).	  The	  
important	   roles	   of	   α7nAChRs	   in	  memory	   and	   synapse	   formation	   are	   due	   to	   the	   Ca2+	  
permeability	  of	  α7nAChRs	  (Broide	  &	  Leslie,	  1999).	  	  	  
	  
	  





1.1.4 Cholinergic	  Tone	  and	  Beta-­‐Amyloid	  	  
The	  α7nAChR	   is	  particularly	  abundant	   in	   the	  basal	   forebrain	   (Ikonomovic	  et	  al.,	  2009),	  
where	  major	  axons	   feed	   into	   the	  hippocampus	  and	  neocortex	   from	  the	  cortex.	   In	  AD,	  
these	  areas	  are	  considered	  vulnerable	  targets	  and	  are	  linked	  to	  the	  early	  manifestations	  
observed	   in	  AD	  patients,	   such	  as	   impairment	  of	  hippocampus-­‐based	  episodic	  memory	  
and	   lack	   of	   attention	   (Doody	   et	   al.,	   2001;	   Minger	   et	   al.,	   2000).	   	   The	   pathological	  
deterioration	   of	   areas	   with	   high	   α7nAChR	   expression	   causes	   cholinergic	   input	   to	   be	  
impaired	   resulting	   in	   part	   of	   AD	   symptoms	   (Gray,	   Rajan,	   Radcliffe,	   Yakehiro,	   &	   Dani,	  
1996;	   Ji,	   Lape,	   &	   Dani,	   2001;	   Rezvani,	   Bushnell,	   &	   Levin,	   2002).	   Moreover,	   the	  
symptomatic	  improvement	  of	  AD	  patients	  upon	  administration	  of	  cholinomimetics	  (Ach-­‐
like	   chemicals)	   (Lopez-­‐Arrieta,	   Rodriguez,	   &	   Sanz,	   2000,	   2001;	   Quirion	   et	   al.,	   1995;	  
Zamani	   &	   Allen,	   2001)	   strengthened	   evidence	   in	   support	   of	   cholinergic	   malfunction	  
being	  relevant	  to	  AD	  symptoms.	  	  
There	   is	  compelling	  evidence	   linking	  Aβ	  to	  alteration	  of	  glutamate	  release	  (Dougherty,	  
Wu,	  &	  Nichols,	  2003;	  Wu,	  Khan,	  &	  Nichols,	  2007)	  and	  localization	  of	  NMDARs	  subunits	  
modulated	  by	  α7nAChR	  through	  Ca2+	   influx.	  α7nAChR	  modulates	  the	  ratio	  of	  NR2A-­‐	  to	  
NR2B-­‐	   containing	   NMDA	   receptors	   on	   the	   synapse	   and	   extra-­‐synapse	   (Snyder	   et	   al.,	  
2005).	   Thus,	   by	   deregulating	   the	   function	   of	   α7nAChR,	   Aβ	   is	   able	   compromise	   the	  
intricate	  ratio	  of	  NR2A-­‐	  to	  NR2B-­‐	  containing	  NMDA	  receptors.	  It	  has	  been	  shown	  that	  Aβ	  
activates	   the	   mitogen-­‐activated	   protein	   kinase	   (MAPK)	   pathway,	   which	   results	   in	   an	  





increase	   in	   AChE	   levels	   through	   activation	   of	   mGluR	   1	   and	   mGluR	   5	   (Small,	   Mok,	   &	  
Bornstein,	   2001).	   The	   subsequent	   increase	   in	   AChE	   activity	   increases	   the	   rate	   of	   Ach	  
degradation	  and,	  consequently	  decreases	  cholinergic	  tone.	  As	  a	  compensatory	  strategy	  
for	   the	   decreased	   synaptic	   activity	   in	   AD,	   postsynaptic	   receptors	   may	   increase	   in	  
number	  (Davis	  &	  Goodman,	  1998).	  Of	  the	  several	  nAChR	  subtypes	  localized	  in	  the	  brain,	  
expression	   of	   α7nAChR	   was	   found	   to	   be	   elevated	   in	   transgenic	   mouse	   models	  
engineered	  to	  produce	  human	  Aβ	  (Bednar	  et	  al.,	  2002;	  Dineley	  et	  al.,	  2001).	  In	  the	  same	  
study,	  the	  increase	  in	  α7nAChR	  was	  observed	  before	  the	  formation	  of	  insoluble	  plaques	  
in	   the	   AD	  mouse	   model,	   which	   emphasized	   the	   role	   of	   the	   soluble	   Aβ	   as	   the	   active	  
species	  causing	  disruption	  of	  cellular	  homeostasis.	  	  
1.1.5 α7nAChRs	  and	  Beta-­‐Amyloid	  	  
Aβ	  was	   found	   to	   bind	   to	   α7nAChR	   in	   picomolar	   affinity	   (Wang,	   Lee,	   D'Andrea,	   et	   al.,	  
2000;	  Wang,	  Lee,	  Davis,	  et	  al.,	  2000)	  and	  to	   induce	   its	  activation	  (Dineley	  et	  al.,	  2002;	  
Dineley	  et	  al.,	  2001).	  	  Interestingly,	  Xenopus	  oocytes	  expressing	  rat	  α7nAChR	  responded	  
with	  small	   currents	   to	  nanomolar	  concentrations	  of	  Aβ	   (Dineley	  et	  al.,	  2002;	  Grassi	  et	  
al.,	   2003).	   The	   small	   currents	  produced	  by	  α7nAChR	   show	   that	  α7nAChR	   can	  become	  
inactive	   if	   continuously	   exposed	   to	   Aβ,	   and/or	   that	   Xenopus	   oocytes	   do	   not	   possess	  
proteins	  needed	  for	  prolonged	  activation	  of	  α7nAChR.	  In	  another	  study,	  treatment	  with	  
picomolar	  Aβ	  concentrations	   led	   to	  sustained	   increases	   in	  presynaptic	  Ca2+	  via	  α7	  and	  
other	   nAChRs	   (Dougherty	   et	   al.,	   2003).	   Furthermore,	   Aβ	   treatment	   resulted	   in	  





intracellular	  Ca2+	  influx	  increase	  in	  mouse	  cortical	  neurons	  derived	  from	  wild-­‐type	  mice	  
but	   not	   in	   neurons	   derived	   from	   the	   α7nAChR-­‐knockout	   (Khan,	   Tong,	   Jhun,	   Arora,	   &	  
Nichols,	  2010;	  Mehta	  et	  al.,	  2009).	  	  
In	  contrast,	  other	  studies	  have	  shown	  that	  Aβ	  blocks	  α7nAChR	  (Liu,	  Kawai,	  &	  Berg,	  2001;	  
Pettit,	   Shao,	   &	   Yakel,	   2001;	   Tozaki	   et	   al.,	   2002).	   Nonetheless,	   in	   these	   studies,	   a	  
relatively	   high	   concentration	   of	   Aβ	   was	   needed	   completely	   block	   α7nAChR.	  
Furthermore,	   blockage	   required	   pre-­‐application	   of	   peptide,	   and	   inhibition	   was	  
reversible	   and	   noncompetitive.	   The	   contradictory	   evidence	   for	   both	   stimulatory	   and	  
inhibitory	   effects	   of	   Aβ	   on	   α7nAChR	   may	   reflect	   a	   complex	   biological	   interaction	  
between	  the	  two	  proteins.	  The	  contrasting	  evidence	  also	  reflects	  different	  types	  of	  cells,	  
different	  stoichiometry	  of	  Aβ	  preparations,	  or	  variable	  detection	  methods	  used	  in	  each	  
laboratory.	  
Cellular	  Prion	  Protein	  (PrPC):	  a	  New	  Player	  in	  AD	  
1.1.6 Cellular	  Prion	  Protein	  	  
	  The	   Cellular	   Prion	   Protein	   (PrPC)	   is	   a	   glycosylphosphatidylinositol	   (GPI)–anchored	  
protein	   present	   at	   the	   cell	   surface	   and	   in	   intracellular	   compartments	   (Madore	   et	   al.,	  
1999).	  PrPC	  is	  highly	  expressed	  in	  both	  the	  central	  and	  peripheral	  nervous	  systems	  from	  
early	  development	  to	  adulthood.	  Moreover,	  PrPC	  is	  important	  in	  signaling	  pathways	  that	  
are	  responsible	  for	  neurotrophic	  activities	  (Chiarini	  et	  al.,	  2002).	  The	  role	  of	  PrPC	  started	  





to	  emerge	  in	  experiments	  where	  PrPC	  expression	  prevented	  neuronal	  cell	  death	  of	  PrPC-­‐
null	   hippocampal-­‐derived	   cells	   cultured	  on	   serum-­‐free	  media	   (Kuwahara	   et	   al.,	   1999).	  
These	  early	  results	  were	  reinforced	  by	  studies	  showing	  a	  possible	  neurotrophic	  role	  for	  
PrPC	  (Coitinho	  et	  al.,	  2007;	  Martins	  et	  al.,	  2010;	  Roffe	  et	  al.,	  2010).	  Some	  authors	  have	  
proposed	  that	  PrPC	  acts	  as	  a	  docking	  element	  on	  the	  cell	  membrane	  integrating	  multiple	  
signaling	  pathways	  by	  scaffolding	  sets	  of	  extracellular	  and	  transmembrane	  molecules	  on	  
lipid	  rafts	  (Martins	  et	  al.,	  2002).	  
	  
1.1.7	   Cellular	  Prion	  Protein	  and	  Beta-­‐Amyloid	  	  
Recently,	  expression-­‐cloning	  experiments	  were	  conducted	  on	  CV1	  Origin	  SV40	  -­‐7	  (COS-­‐
7)	   cells	   to	   identify	   receptors	   for	   Aβ	   oligomers.	   COS-­‐7	   cells	   were	   chosen	   for	   the	  
expression	   cloning	   experiments	   because	   they	   showed	   low	   levels	   of	   binding	   of	   Aβ	  
oligomers	   compared	   to	  hippocampal	   cells.	   These	  unbiased	   studies	   identified	  PrPC	  as	   a	  
high-­‐affinity	   binding	   site	   for	   Aβ	   oligomers	   (Lauren	   et	   al.,	   2009).	   Aβ	   oligomers	   bind	   to	  
PrPC	  on	  amino	  acids	  95-­‐110	  (Lauren	  et	  al.,	  2009)	  and	  23-­‐27	  (Chen	  et	  al.,	  2010).	  The	  PrPC	  
95-­‐110	   stretch	   of	   amino	   acids	   lies	   within	   an	   unstructured	   central	   domain	   of	   PrPC	  
involved	  in	  neuronal	  toxicity	  in	  vitro	  and	  in	  neurodegeneration	  in	  mice	  (Baumann	  et	  al.,	  
2007).	  	  





On	  mice	  hippocampal	  slices,	  Aβ	  oligomer	   treatment	  resulted	   in	  a	  decrease	   in	  synaptic	  
strength	   in	   a	   PrPC-­‐dependent	   fashion.	   Despite	   the	   fact	   that	  many	   subsequent	   studies	  
confirmed	   the	   binding	   of	   Aβ	  oligomers	   to	   PrPC	  (Chen	   et	   al.,	   2010;	   Chung	   et	   al.,	   2010;	  
Lauren	   et	   al.,	   2009),	   not	   all	   studies	   found	   that	   the	   effects	   of	  Aβ	   are	   PrPC	  –dependent	  
(Calella	  et	  al.,	  2010;	  Kessels,	  Nguyen,	  Nabavi,	  &	  Malinow,	  2010).	  This	  controversy	  may	  
be	  related	  to	  variations	  in	  the	  methodology	  used	  to	  study	  synaptic	  plasticity,	  the	  source	  
of	  Aβ	  peptides	  or	  the	  animal	  models	  used.	  Although	  binding	  of	  PrPC	  to	  Aβ	  oligomers	  and	  
the	   consequences	   of	   this	   binding	   to	   synaptic	   plasticity	  were	   described,	   the	  molecular	  
mechanisms	  leading	  to	  pathogenesis	  are	  not	  understood.	  	  
	  
1.1.8	   Cellular	  Prion	  Protein	  and	  AD	  	  
The	   methionine/valine	   (M129V	   M129V)	   polymorphism	   of	   the	   PrPC	   gene,	   PRNP,	   is	  
suspected	   to	   have	   links	   with	   the	   sporadic	   form	   of	   AD.	   Homozygosity	   at	   this	   codon	  
resulted	  in	  variations	  at	  the	  unstructured	  central	  domain	  of	  PrPC,	  the	  domain	  where	  Aβ	  
oligomers	  bind	  to	  PrPC.	  The	  variations	  at	  the	  unstructured	  domain	  of	  PrPC	  were	  linked	  to	  
Creutzfeldt-­‐Jakob	   disease,	   a	   neurodegenerative	   disease	   resulting	   from	   the	   improper	  
folding	  of	  PrPC	  (Palmer,	  Dryden,	  Hughes,	  &	  Collinge,	  1991).	  One	  study	  showed	  that	  the	  
(M129V)	   genetic	   variation	   is	   linked	   to	   increased	   risk	   of	   AD	   (Del	   Bo	   et	   al.,	   2006).	  
However,	  there	  is	  no	  evidence	  indicating	  that	  the	  molecular	  basics	  of	  the	  link	  between	  





the	  M129V	  polymorphism	  and	  risk	  of	  AD	  is	  due	  to	  increased	  binding	  of	  Aβ	  oligomers	  to	  
PrPC.	  	  
Moreover,	   there	   is	  conflicting	  evidence	  regarding	   the	  cognitive	  deficits	  and	  behavioral	  
abnormalities	   observed	   in	   AD	   mouse	   models.	   Lack	   of	   PrPC	   rescued	   behavioral	  
abnormalities	  and	  early	  death	  in	  a	  mouse	  model	  of	  AD	  (Gimbel	  et	  al.,	  2010).	  However,	  
AD-­‐related	  behavioral	  abnormalities	  were	  not	  PrPC-­‐dependent	  in	  another	  paper	  dealing	  
with	  a	  different	  mouse	  model	  of	  AD	  (Cisse	  et	  al.,	  2011).	  	  
	  
1.2 Stress	  Induced	  Protein	  1:	  a	  PrPC	  ligand	  
1.2.1	   Stress	  Induced	  Protein	  1	  (STI1)	  	  
	  The	  STI1	  protein	  is	  a	  conserved	  66-­‐kDa	  protein	  found	  in	  many	  distant	  species.	  STI1	  was	  
originally	  discovered	  in	  yeast	  where	  it	  was	  shown	  to	  interact	  with	  heat	  shock	  protein	  70	  
and	  90	  (HSP	  70	  and	  HSP	  90),	  and	  this	  interaction	  is	  important	  for	  the	  proper	  folding	  of	  
proteins	   (Bukau,	   Weissman,	   &	   Horwich,	   2006;	   Caplan,	   Mandal,	   &	   Theodoraki,	   2007;	  
Picard,	   2006;	   Pratt	   &	   Toft,	   1997,	   2003;	   Wegele,	   Muller,	   &	   Buchner,	   2004).	   STI1-­‐null	  
embryos	   did	   not	   survive	   past	   an	   early	   developmental	   embryonic	   phase,	   indicating	   an	  
important	   role	   of	   STI1	   in	   mouse	   embryogenesis	   (Beraldo	   et	   al.,	   in	   preparation).	  
Furthermore,	  mouse	   embryonic	   fibroblasts	   derived	   from	   STI1-­‐null	   embryos	   could	   not	  
survive	  in	  culture	  (Beraldo	  et	  al.,	  in	  preparation).	  The	  fact	  that	  STI1	  deficiency	  produces	  





a	   lethal	  phenotype	  provides	  evidence	   that	  STI1	  may	  have	  a	   crucial	   role	  at	   the	  cellular	  
level.	  
1.2.2	   Stress	  Induced	  Protein	  1,	  PrPC,	  and	  α7nAChR	  complex	  	  
	  The	  interaction	  between	  STI1	  and	  PrPC	  was	  originally	  discovered	  in	  1997.	  At	  that	  time,	  it	  
was	  thought	  that	  STI1	  acted	  as	  a	  PrPC	  receptor	  (Martins	  et	  al.,	  1997).	  Regardless	  of	  the	  
nature	   of	   the	   interaction,	   PrPC	   and	   STI1	   binding	   resulted	   in	   activation	   of	   signaling	  
pathways	   such	   as	   the	   cAMP-­‐Protein	   Kinase	   A	   and	   MAPK	   pathways	   leading	   to	  
neurotrophic	   activities	   (Chiarini	   et	   al.,	   2002;	   Zanata	   et	   al.,	   2002).	   Later,	   it	  was	   shown	  
that	   STI1	   is	   neuroprotective	   and	   induces	   neuritogenesis	   in	   a	   PrPC-­‐dependent	   fashion	  
when	  binding	  to	  neurons	  (Lopes	  et	  al.,	  2005).	  In	  2007,	  a	  different	  theory	  was	  proposed	  
for	  the	  interaction	  between	  STI1	  and	  PrPC.	  STI1	  was	  described	  as	  a	  PrPC	  ligand	  secreted	  
by	  astrocytes	  that	  can	  protect	  against	  cell	  death	  (Lima	  et	  al.,	  2007).	  Moreover,	  infusion	  
of	   the	   rat	   hippocampus	   with	   antibodies	   for	   PrPC	   and	   STI1	   resulted	   in	   cognitive	  
behavioral	   deficits	   (Coitinho	   et	   al.,	   2007).	   Overall,	   these	   results	   suggest	   that	   the	  
interaction	   of	   PrPC	   and	   STI1	   may	   be	   important	   for	   general	   neurotrophic	   actions	   and	  
cognitive	  functioning.	  
In	   an	   attempt	   to	   elucidate	   the	   cellular	   functions	   and	   signaling	   pathways	   activated	   by	  
STI1,	   recent	   studies	  demonstrated	   that	  Ca2+	   signaling	  may	  be	   the	   trigger	   for	   the	  STI1-­‐
mediated	   and	   PrPC-­‐dependent	   physiological	   functions	   (Beraldo	   et	   al.,	   2010).	   Indeed,	  





recent	   results	   showed	  that	   the	  α7nAChR	   is	   required	   for	   transduction	  of	   signals	  by	   the	  
STI1-­‐PrPC	   complex	   by	   allowing	   Ca2+	  influx	   into	   neurons	   (Beraldo	   et	   al.,	   2010).	   Further,	  
the	   same	   study	   showed	   that	   the	   STI1-­‐induced	   neuroprotection	   is	   dependent	   on	   PrPC	  
and	  α7nAChR.	  	  
	  
1.3	   Aβ	  oligomers	  and	  Stress	  Induced	  Protein	  1	  
There	   is	   evidence	   that	   STI1	   and	  Aβ	   oligomers	  may	   need	   PrPC	   to	   execute	   their	   effects	  
(Beraldo	   et	   al.,	   2010;	   Chiarini	   et	   al.,	   2002;	   Lauren	   et	   al.,	   2009;	   Lopes	   et	   al.,	   2005;	  
Resenberger,	  Winklhofer,	  &	  Tatzelt,	  2012;	  Zanata	  et	  al.,	  2002).	  The	  binding	  sites	  of	  both	  
STI1	  and	  Aβ	  are	  adjacent	  on	  PrPC	  (Chen	  et	  al.,	  2010;	  Lauren	  et	  al.,	  2009;	  Zanata	  et	  al.,	  
2002).	   Also,	   there	   is	   evidence	   that	   STI1	   and	   Aβ	   oligomers	   require	   the	   presence	   of	  
α7nAChR	   to	   induce	   Ca2+	   influx	   (Beraldo	   et	   al.,	   2010;	   Dougherty	   et	   al.,	   2003).	  
Nonetheless,	   STI1	   and	   Aβ	   oligomers	   have	   completely	   different	   effects	   on	   neurons;	  
neurotrophic	   versus	   neurotoxic,	   respectively.	   Therefore,	   there	   may	   be	   competition	  
between	  STI1	  and	  Aβ	  oligomers	  for	  the	  PrPC-­‐α7nAChR	  complex.	  
Treatment	   of	   neurons	   with	   Aβ	   oligomers	   have	   been	   shown	   to	   result	   in	   Extracellular	  
Regulated	   Kinases	   1/2	   (ERK1/2)	   phosphorylation	   (Chong	   et	   al.,	   2006;	   Ghribi,	  
Prammonjago,	  Herman,	  Spaulding,	  &	  Savory,	  2003;	  Ma	  et	  al.,	  2007).	  In	  a	  recent	  study	  it	  
was	  shown	  that	  Aβ-­‐induced	  ERK	  1/2	  phosphorylation	  may	  be	  PrPC-­‐dependent	  (Caetano	  





et	   al.,	   2011).	   Activation	   of	   ERK	   1/2	   is	   a	   common	   signaling	   pathway	   activated	   by	   Aβ	  
peptides	  and	  at	  least	  one	  report	  suggests	  that	  this	  Aβ	  effect	  is	  dependent	  on	  α7nAChRs	  
(Dineley	   et	   al.,	   2001).	   STI1	   is	   also	   known	   to	   activate	   ERK1/2	   phosphorylation	   after	  
binding	   to	   PrPC	   and	   induce	   neuritogenesis	   (Lopes	   et	   al.,	   2005).	   Although	   both	   ligands	  
activate	   ERK1/2,	   each	   ligand	   can	   do	   so	   in	   different	   ways.	   The	   duration	   and	   the	  
localization	  of	  the	  ERK1/2	  activation	  can	  be	  different	  for	  both	  ligands.	  	  	  
1.3.1	   Evidence	  for	  Direct	  Competition	  on	  PrPC	  
The	  binding	   sites	  of	  Aβ	  oligomers	   and	  STI1	  on	  PrPC	   are	   adjacent.	   STI1	  binds	   to	   amino	  
acids	  113-­‐125	  on	  PrPC	  (Zanata	  et	  al.,	  2002);	  on	  the	  other	  hand,	  one	  of	  the	  binding	  sites	  
of	  Aβ	  oligomers	   to	  PrPC	   spans	  amino	  acids	  90-­‐105	   (Lauren	  et	  al.,	  2009).	  Using	  Surface	  
Plasmon	  Resonance,	  our	  laboratory	  has	  studied	  the	  interaction	  between	  PrPC,	  STI1,	  and	  
Aβ	   oligomers.	   These	   results	   show	   that	   STI1	   and	   Aβ	   oligomers	   cannot	   bind	   to	   PrPC	  
concurrently,	   and	   that	   a	   competitive	  nature	  may	  exist	   between	   the	   two	   ligands	  upon	  
binding	  to	  PrPC	  (Beraldo	  et	  al.,	  unpublished).	  	  
1.3.2	   Potential	  Roles	  for	  STI1	  against	  Aβ	  oligomers	  and	  in	  AD	  	  
In	   unpublished	  work	   conducted	   in	   collaboration	  with	   Dr.	   Vima	  Martin’s	   laboratory,	   it	  
was	  demonstrated	  that	  STI1	  prevents	  the	  loss	  of	  synapses	  induced	  by	  Aβ	  oligomers	  on	  
cultured	  neurons	  in	  a	  PrPC-­‐dependent	  fashion	  (Hajj	  et	  al	  unpublished).	  Furthermore,	  in	  
order	  to	  study	  the	  effect	  of	  STI1	  in	  a	  mouse	  model	  that	  reproduces	  neurodegenerative	  





diseases,	   our	   laboratory	   started	   by	   quantifying	   the	   level	   of	   STI1	   in	   a	  mouse	  model	   of	  
Alzheimer’s	  disease	  (APPSwe/PS1dE9).	  The	  transgenic	  mouse	  model	  shows	  progressive	  
accumulation	   of	   Aβ	   oligomers	   and	   increased	   plaque	   load	   (Ashe	   &	   Zahs,	   2010;	  
Duyckaerts,	  Potier,	  &	  Delatour,	  2008).	  	  In	  this	  mouse	  model,	  levels	  of	  STI1	  decreased	  by	  
50%	  during	  the	   initiation	  of	  amyloidosis	   (6	  months),	  and	  this	  may	  be	  due	  to	   increased	  
degradation	  of	   the	  protein.	   Interestingly,	   the	   levels	  of	   STI1	  are	   restored	  back	  after	  an	  




































Overall,	   STI1	   neurotrophic	   functions	   have	   been	   shown	   to	   be	   PrPC-­‐	   and	   α7nAChR-­‐
dependent	   (Beraldo	  et	  al.,	  2010),	  which	  suggested	  that	  STI1	  utilizes	  the	  PrPC-­‐α7nAChR	  
complex.	  As	  suggested	  by	  recent	  studies,	  STI1	  neurotrophic	  functions	  may	  be	  important	  
in	  protecting	  neurons	  against	  different	  neuronal	   insults	   (Chiarini	  et	  al.,	  2002;	  Lopes	  et	  
al.,	   2005;	   Zanata	   et	   al.,	   2002).	   The	   reduced	   levels	   of	   STI1	   in	   the	   APPSwe/PS1dE9	   AD	  
mouse	   model	   suggested	   that	   STI1	   may	   be	   degraded.	   The	   consequences	   of	   reduced	  
levels	  of	  STI1	  in	  AD-­‐related	  pathology	  are	  not	  known.	  On	  the	  other	  hand,	  the	  binding	  of	  
Aβ	  oligomers	  to	  PrPC	  (Chen	  et	  al.,	  2010;	  Lauren	  et	  al.,	  2009),	  the	  reported	  PrPC-­‐mediated	  
Aβ	   neurotoxicity(Lauren	   et	   al.,	   2009;	   Nygaard	   &	   Strittmatter,	   2009),	   and	   the	  
involvement	  of	  this	  binding	  domain	  in	  neurodegenerative	  diseases	  (Palmer	  et	  al.,	  1991)	  
strengthened	  the	  possibility	   for	  a	  PrPC	  role	   in	  AD.	  However,	  PrPC	  can	  also	  bind	   to	  STI1	  
and	  mediate	  its	  neurotrophic	  effects	  (Chiarini	  et	  al.,	  2002;	  Lopes	  et	  al.,	  2005;	  Zanata	  et	  
al.,	  2002).	  Further,	  the	  involvement	  of	  α7nAChR	  in	  the	  pathology	  of	  AD	  (Dineley	  et	  al.,	  
2002;	  Dineley	  et	  al.,	  2001;	  Dougherty	  et	  al.,	  2003;	  Dziewczapolski,	  Glogowski,	  Masliah,	  &	  
Heinemann,	  2009)	  and	   its	  necessity	   in	  mediating	  the	  neurotrophic	  actions	  of	  the	  STI1-­‐
PrPC	  (Beraldo	  et	  al.,	  2010)	  strengthens	  the	  possibility	  for	  a	  PrPC-­‐α7nAChR	  complex	  role	  in	  
the	  pathological	  aspects	  of	  AD	  and	  in	  normal	  neural	  physiology.	  	  
It	  is	  unknown	  if	  Aβ	  requires	  PrPC	  and	  α7nAChR	  as	  a	  complex	  to	  mediate	  its	  neurotoxicity.	  
Thus,	   STI1	  might	   be	   able	   to	   protect	   against	   Aβ	   because	   Aβ	  may	   also	   utilize	   the	   PrPC-­‐





α7nAChR.	  Understanding	  how	  STI1	  may	  be	  able	  to	  protect	  against	  Aβ	  through	  the	  PrPC-­‐
α7nAChR	  complex	  may	  give	  us	  insights	  into	  a	  new	  potential	  therapeutic	  target,	  the	  PrPC-­‐
α7nAChR	  complex.	  	  
	  
2.2	   Hypothesis	  
	  STI1	  blocks	   the	  deleterious	  effects	  of	  Aβ	  oligomers	  on	  neurons	  via	   the	  PrPC-­‐α7nAChR	  
complex.	  
Objective	   1:	   Study	   the	   effect	   of	   Aβ	   oligomers	   on	   the	   PrPC-­‐α7nAChR	   complex	   with	  
respect	  to	  Ca2+	  influx	  and	  cell	  death	  
Objective	   2:	   Assess	   the	   ability	   of	   STI1	   in	   protecting	   against	   oligomeric	   Aβ-­‐mediated	  




































3.1	   Animals,	  Neuronal	  Preparation,	  and	  Cultures	  	  	  
Heterozygous	   STI1	   knockout	  mice	   were	   generated	   as	   described	   by	   Beraldo	   et	   al.,	   (in	  
preparation).	  Briefly,	  non-­‐conditional	  heterozygous	  STI1	  knockout	  mice	  were	  generated	  
by	   Ozgene	   (Australia)	   using	   standard	   homologous	   recombination	   techniques	   on	  
C57BL/6jES	  embryonic	  stem	  cells.	  Firstly,	  chimeric	  mice	  were	  bred	  to	  C57BL/6j	  mice	  to	  
result	   in	   germline	   transmission	   of	   the	   floxed	   STI1	   allele.	   Subsequently,	   F1	  mice	  were	  
crossed	  to	  universal	  Cre	  mice	  to	  remove	  loxP	  flanked	  regions.	  The	  Cre	  recombined	  mice	  
were	   then	   bred	   to	   C57BL/6j	   mice	   and	   the	   progeny	   was	   used	   to	   expand	   the	   mouse	  
colony.	   PrPC-­‐knockout,	   generously	   donated	   by	   the	   Jirik	   laboratory,	   and	   α7nAChR-­‐
knockout,	   generously	   donated	   by	   the	   Jackson	   laboratory,	   mice	   were	   generated	   as	  
described	  by	  Büeler	  et	  al.,	  1992	  and	  Orr-­‐Urtreger	  et	  al.,	  1997	  (Manson	  et	  al.,	  1994;	  Orr-­‐
Urtreger	   et	   al.,	   1997),	   respectively.	   Primary	   cultured	   neurons	  were	   derived	   from	   E17	  
embryos	  by	  extracting	  the	  hippocampus	  from	  the	  embryonic	  brains.	  Subsequently,	  they	  
were	   kept	   in	   vitro	   for	   5	   or	   11	   days	   before	   treatment.	   For	   cell	   death	   assays	   using	  
neurons,	   1.0X105	   cells	   were	   plated	   on	   24-­‐well	   plates	   or	   4-­‐well	   plates.	   Neurons	   were	  
initially	   plated	   in	  wells	   coated	  with	   Poly-­‐L-­‐Lysine	   using	   neuronal	   plating	  medium.	   The	  
media	  consisted	  of	  10%	  heat	   inactivated	  Fetal	  Bovine	  Serum	  (Invitrogen,	  Grand	  Island,	  
NY),	   0.45%	   glucose	   (BioRad,	   Hercules,	   CA),	   1%	   Sodium	   Pyruvate	   (Invitrogen),	   1%	  
Glutamine	  (Invitrogen),	  1%	  Penicillin/Streptomycin	  (Invitrogen),	  and	  Minimum	  Essential	  
Media	  (MEM)	  (Invitrogen).	  	  Two	  to	  four	  hours	  after	  plating,	  wells	  were	  gently	  shaken	  by	  





hand	  to	  remove	  any	  non-­‐adherent	  cells	  and	  plating	  medium	  was	  replaced	  with	  neuronal	  
maintenance	   medium.	   The	   maintenance	   media	   contained	   2%	   B-­‐27	   supplement	  
(Invitrogen),	   1%	   Glutamine,	   1%	   Penicillin/Streptomycin	   and	   Neurobasal	   medium	  
(Invitrogen).	  Neurons	  were	  then	  cultured	  at	  37	  °C	  for	  5	  or	  11	  days	  in	  vitro	  (DIV).	  
	  
3.2	   Preparation	  of	  Aβ	  Oligomers	  and	  Recombinant	  STI1	  	  
Aβ	  peptide	  was	  purchased	  from	  r-­‐peptide	  company,	  cat#	  A-­‐1002-­‐2	  and	  oligomers	  were	  
prepared	   in	   the	   laboratory	   according	   to	  Barghorn	  et	   al.,	   2005	   (Barghorn	  et	   al.,	   2005).	  
Briefly,	   Aβ	   peptide	   (1–42)	   was	   stored	   at	   −80°C	   prior	   to	   resuspension	   and	   was	  
monomerized	   in	   1,1,1,3,3,3-­‐hexafluoro-­‐2-­‐propanol	   (HFIP,	   Sigma	   H-­‐8508).	   	   After	   being	  
stored	  at	   -­‐80°C,	   anhydrous	  DMSO	  was	   added	   to	   the	   samples.	   The	   samples	  were	   then	  
sonicated	  and	   left	   to	  oligomerize	  at	  4°C	   for	  24	  hours.	  Samples	  were	  then	   left	  at	   -­‐80°C	  
until	  used	  for	  the	  studies.	  A	  scrambled	  peptide	  purchased	  from	  the	  same	  company	  (r-­‐
Peptide,	   Cat	   #	   A-­‐1004-­‐2)	   was	   prepared	   using	   the	   same	   procedures	   as	   for	   the	   non-­‐
scrambled	   form	  and	  was	  used	  as	   a	  negative	   control.	  All	   oligomeric	  preparations	  were	  
verified	  using	  western	  blotting	  before	  using	  them	  to	  treat	  our	  cultures.	  	  	  	  	  	  	  	  
Recombinant	   STI1	  was	  prepared	  according	   to	  Zanata	  et	   al.,	   2002	   (Zanata	  et	   al.,	   2002)	  
and	   kindly	   provided	   by	   Ms.	   Sanda	   Raulic.	   Briefly,	   protein	   expression	   was	   induced	   in	  
Escherichia	   coli	   DH-­‐5α	   by	   isopropyl-­‐β-­‐D-­‐thiogalactopyranoside	   (IPTG).	   	   E.	   coli	   DH-­‐5α	  





contains	   the	  expression	  vector	  His6-­‐STI1.	  Bacteria	  cells	  were	   then	   resuspended	   in	   lysis	  
buffer	  and	  lysed	  in	  French	  press.	  Protein	  purification	  then	  followed.	  
	  The	  concentration	  of	  STI1	  used	  for	  all	  experiments	  was	  1μM.	  For	  the	  cell	  death	  assay,	  
neurons	  were	   incubated	  with	  1μM	  STI1	   for	  1	  hour	  at	  37	   °C	  before	   treatment	  with	  Aβ	  
oligomers.	   For	  Ca2+	   signaling	   experiments,	   STI1	   (1μM)	  was	  directly	   added	   to	   the	  Ca2+-­‐
supplemented	  buffer.	  
3.3	   Cell	  Death	  Assay	  	  
Primary	   hippocampal	   neurons	   (1X104)	   were	   treated	   with	   Aβ	   oligomers	   (1μM)	   for	   48	  
hours	  5	  or	  11	  days	  after	  culture.	   	  For	  treatments	   involving	  STI1	  or	  STI1Δ230-­‐245,	  neurons	  
were	   preincubated	  with	   STI1	   (1μM)	   or	   STI1Δ230-­‐245	  (1μM)	   for	   1	   hour	   and	   then	   treated	  
with	  Aβ	  oligomers	  (100nM,	  500nM,	  1μM,	  and	  3μM)	  for	  24	  hours	  or	  48	  hours.	  The	  cell	  
death	   assay	   used	   was	   the	   LIVE/DEAD®	   Viability/Cytotoxicity	   Kit	   (Invitrogen)	   for	  
mammalian	   cells.	   This	   kit	   contains	   Calcein-­‐AM	   (Ex/Em	   494nm/517nm	   -­‐	   green)	   that	  
labels	   live	   cells	   and	   Ethidium	   Homodimer-­‐1	   (517nm/617nm	   Ex/Em	   -­‐	   red)	   that	   labels	  
dead	  cells.	  Calcein-­‐AM	  gets	  into	  live	  cells	  via	  the	  AM	  hydrophobic	  group	  and	  fluoresces	  
after	   the	   AM	   group	   is	   cleaved	   off	   by	   the	   esterase	   activity	   of	   live	   cells.	   Ethidium	  
homodimer	   1	   gets	   into	   dead	   cells	   with	   ruptured	  membranes	   and	   binds	   to	   DNA.	  The 
images of 5-8 fields were taken using a Zeiss LSM-510 confocal microscope (Carl Zeiss, 
Oberkochen, Germany). Image J software was used for counting cells following cell 
imaging.  The	  formula	  [#	  of	  dead	  cells	  (red	  cells)/#	  of	  dead	  cells	  (red	  cells)	  +	  #	  of	  viable	  
cells	   (green	   cells)]	   X	   100	   was	   used	   to	   calculate	   the	   %	   of	   cell	   death	   among	   neuronal	  





cultures.	   At	   least	   3	   independent	   experiments	   were	   conducted	   for	   testing	   PrPC-­‐
dependent	  cell	  death.	  At	  least	  10	  independent	  experiments	  were	  conducted	  for	  testing	  
the	   sensitivity	   of	   STI1	   heterozygous-­‐knockout	   neurons.	   One-­‐way	   ANOVA	   and	   the	  
Newman	  Keuls	  posttest	  were	  used	  for	  statistical	  analysis.	  	  
3.4	   Ca2+	  Imaging	  
For	  Ca2+	  imaging,	  the	  UV	  excitable,	  ratiometric	  (ratio	  of	  double	  excitation	  wavelengths)	  
Ca2+	   indicator	   Fura-­‐2	   (Ex	   345/380,	   EM	   510)	   (Invitrogen)	   (Tsien,	   Rink,	   &	   Poenie,	   1985)	  
was	  used	  to	  quantify	  Ca2+	  influx	  in	  neurons.	  Fura-­‐2	  has	  an	  AM	  group	  that	  allows	  Fura-­‐2	  
to	  get	  passed	  the	  cell	  membrane	  into	  the	  cytosol	  of	  the	  cell.	  The	  AM	  gets	  cleaved	  off	  by	  
the	  esterase	  activity	  of	  the	  cell	  and	  it	  gets	  excited	  at	  380nm	  wavelength	  when	  its	  Ca2+-­‐
free	  and	  excited	  at	  340	  nm	  when	  its	  Ca2+-­‐bound.	  
After	   plating	   neurons	   on	   gamma	   irradiated	   35	   mm	   uncoated	   glass	   bottom	   (14	   mm	  
microwell)	  culture	  dishes	  purchased	  from	  MatTek	  Corporation,	  neurons	  (4.1	  X	  104	  cells)	  
were	  kept	  5	  days	  or	  11	  days	  in	  vitro	  (DIV).	  Subsequently,	  cells	  were	  loaded	  with	  10	  µM	  
Fura-­‐2	   diluted	   in	   neurobasal	   medium	   for	   40	   minutes.	   Cells	   were	   then	   washed	   three	  
times	  with	  Ca2+-­‐free	  1	  X	  Kreb’s	  buffer	  (1.3	  M	  NaCl,	  25	  mM	  KCl,	  250	  nM	  NaHCO3,	  12	  mM	  
NaH2PO4,	   12	   mM	   MgCl2)	   made	   in	   our	   laboratory.	   Subsequently,	   Kreb’s	   buffer	  
supplemented	  with	  Ca2+	  to	  a	  final	  concentration	  of	  1mM	  was	  added	  to	  the	  cells	  on	  the	  
dish.	  Cells	  were	  kept	  at	  37°C	  for	  an	  extra	  20	  minutes	  for	  the	  AM	  group	  on	  Fura-­‐2	  to	  be	  





hydrolysed	   before	   imaging.	   Differential	   interference	   contrast	   (DIC)	   light	   was	   used	   to	  
focus	  on	  cells.	  Cells	  were	  subsequently	   imaged	  using	  excitation	  detection	  wavelengths	  
340	  nm	  and	  380	  nm,	  alternatively.	   Imaging	  of	  each	  dish	  took	  approximately	  5	  minutes	  
from	   the	   point	   of	   adding	   either	   STI1	   or	   Aβ	   oligomers.	   Approximately	   15-­‐30	   neurons	  
were	  present	  in	  every	  field	  taken	  for	  Ca2+	  imaging.	  	  
For	  analysis	  of	  Ca2+	   influx,	   the	  excitation	  ratio	   (F340/F380)	  of	   the	  ratiometric	   indicator	  
Fura-­‐2	   and	   time	   were	   recorded	   in	   Excel.	   Each	   cell	   was	   analyzed	   individually	   and	  
quantification	   of	   increase	   in	   Ca2+	   influx	  was	   averaged	   for	   all	   responding	   cells	   on	   each	  
dish.	  Cells	  that	  did	  not	  respond	  were	  excluded	  from	  the	  analysis.	  Each	  dish	  with	  neurons	  
























4.1	   Aβ	   oligomers	   require	   both	   PrPC	   and	   α7nAChR	   for	   sustained	   increase	   in	  
intracellular	  Ca2+	  and	  PrPC	  for	  cell	  death	  	  
	  
Some	  studies	  suggested	  that	  Aβ	  oligomers	  might	  disrupt	  Ca2+	  homeostasis	  in	  neurons	  by	  
compromising	  the	  mitochondrial	  and	  endoplasmic	  reticulum	  Ca2+	  buffering	  mechanisms	  
(Guo	  et	  al.,	  1996),	  and	  disruption	  in	  Ca2+	  homeostasis	  has	  been	  linked	  to	  cellular	  stress	  
and	   neuronal	   death	   (Zundorf	   &	   Reiser,	   2011).	   Both	   PrPC	   and	   α7nAChRs	   have	   been	  
shown	  to	   interact	  with	  Aβ	  oligomers	   (Lauren	  et	  al.,	  2009;	  Wang,	  Lee,	  D'Andrea,	  et	  al.,	  
2000;	  Wang,	  Lee,	  Davis,	  et	  al.,	  2000)	  and	  to	  regulate	  intracellular	  Ca2+	  levels.	  In	  order	  to	  
understand	   how	   Aβ	   oligomers	   can	   induce	   neuronal	   death,	   we	   treated	   11	   DIV	  
hippocampal	   neurons	   derived	   from	   wild-­‐type,	   PrPC-­‐knockout,	   and	   α7nAChR-­‐knockout	  
mice	  with	  Aβ	  oligomers	  and	  performed	  Ca2+	  signaling	  experiments	  using	  Fura-­‐2	  AM	  Ca2+	  
indicator.	   Primary	   neuronal	   cultures	   derived	   from	  wild-­‐type	  mice	   showed	   a	   sustained	  
increase	  in	  intracellular	  Ca2+	  levels	  when	  treated	  with	  Aβ	  oligomers	  (Figure	  1).	  However,	  
the	  same	  treatment	  with	  Aβ	  oligomers	  resulted	  in	  a	  transient	  intracellular	  Ca2+	  increase	  
in	   neuronal	   cultures	   derived	   from	   PrPC-­‐knockout	   and	  α7nAChR-­‐knockout	  mice	   (Figure	  
1).	  These	  results	   suggest	   that	  Aβ	  oligomers	  might	  need	  both	  PrPC	  and	  α7nAChR	   for	  at	  
least	  part	  of	  the	  Ca2+	  response	  in	  neurons.	  Neuronal	  death	  induced	  by	  Aβ	  oligomers	   is	  
attenuated	  in	  PrPC-­‐null	  mice	  (Kudo	  et	  al.,	  2012).	  To	  determine	  if	  neurotoxicity	   induced	  
by	  Aβ	  oligomers	   is	  dependent	  on	   the	  expression	  of	  PrPC,	  we	   treated	  11	  DIV	  wild	   type	  
and	   PrPC-­‐knockout	   hippocampal	   neurons	  with	   Aβ	   oligomers	   and	  measured	   cell	   death	  





using	  a	  Live/Dead	  staining	  assay.	  Primary	  hippocampal	  neurons	  obtained	  from	  wild	  type	  
mice	  were	  significantly	  more	  sensitive	  to	  500	  nM	  and	  1μM	  Aβ	  oligomers	  than	  their	  PrPC-­‐
knockout	   counterparts	   (Figure	   2	   A&B).	   On	   the	   other	   hand,	   treatment	   with	   3μM	   Aβ	  
oligomers	   resulted	   in	   similar	   levels	   of	   neuronal	   death	   in	   both	   wild	   type	   and	   PrPC-­‐
knockout	   neurons	   (Figure	   2B).	   Overall,	   these	   results	   suggest	   that	   neuronal	   death	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4.2	   Action	  of	  STI1	  is	  dependent	  on	  α7nAChR	  for	  elevation	  of	  intracellular	  Ca2+	  	  
STI1	   activates	   Ca2+	   influx	   in	   neurons	   via	   α7nAChR.	   Recent	   experiments	   demonstrated	  
that	  activation	  of	  PrPC	  by	  STI1	  in	  neurons	  increases	  intracellular	  Ca2+	  level	  (Beraldo	  et	  al.,	  
2010).	   Ca2+	   influx	   activated	   a	   cascade	   of	   downstream	   signaling	   pathways,	   including	  
ERK1/2	   phosphorylation	   and	   PKA	   activation,	   which	   led	   to	   neuritogenesis	   and	  
neuroprotection,	   respectively	   (Lopes	   et	   al.,	   2005).	   It	   was	   also	   demonstrated	   that	   the	  
STI1-­‐induced	   increase	   in	   intracellular	   Ca2+	   on	   neurons	   was	   inhibited	   by	   alpha	  
bungaratoxin	   (α-­‐bgt),	   a	   selective	   α7nAChR-­‐specific	   antagonist	   (Beraldo	   et	   al.,	   2010).	  
Moreover,	  STI1-­‐PrPC	  signaling	  could	  be	  reconstituted	   in	  HEK-­‐293	  cells	   transfected	  with	  
α7nAChRs	   (Beraldo	   et	   al.,	   2010).	   To	   further	   test	   if	   α7nAChRs	   have	   a	   role	   in	   STI1-­‐
mediated	   signaling,	   we	   used	   α7nAChR-­‐KO	   hippocampal	   neurons.	   STI1	   was	   able	   to	  
induce	  increases	  of	   intracellular	  Ca2+	  on	  5	  DIV	  hippocampal	  neurons	  derived	  from	  wild	  
type	   mice,	   but	   not	   on	   hippocampal	   neurons	   derived	   from	   α7nAChR-­‐knockout	   mice	  
(Figure	   3A&B).	   However,	   treatment	   of	   the	   same	   neurons	   with	   the	   Ca2+	   ionophore	  
Ionomycin	  resulted	  in	  an	  increase	  of	   intracellular	  Ca2+	   in	  both	  wild	  type	  and	  α7nAChR-­‐
knockout	  neurons	  (data	  not	  shown).	  These	  results	  suggest	  that	  α7nAChR	  is	  needed	  on	  
neurons	  for	  Ca2+	  influx	  induced	  by	  STI1.	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4.3	   STI1-­‐heterozygous	  knockout	  neurons	  show	  increased	  sensitivity	  to	  Aβ	  oligomers	  	  
Both	  STI1	  and	  Aβ	  oligomers	  bind	  to	  PrPC	  and	  they	  both	  seem	  to	  use	  PrPC	  and	  α7nAChRs	  
to	  induce	  an	  increase	  in	  neuronal	  Ca2+.	  	  However,	  whereas	  STI1	  promotes	  protection	  of	  
neurons	  (Lopes	  et	  al.,	  2005;	  Zanata	  et	  al.,	  2002),	  Aβ	  oligomers	  are	  toxic	  (Yankner	  et	  al.,	  
1989).	  To	  determine	  if	  endogenous	  STI1	  could	  play	  a	  role	  in	  protecting	  neurons	  against	  
Aβ-­‐induced	   toxicity,	   we	   treated	   11	   DIV	   wild-­‐type	   and	   STI1	   heterozygous	   knockout	  
hippocampal	   neurons	   with	   Aβ	   oligomers	   for	   48	   hours.	   	   Heterozygous	   knockout	   mice	  
present	   a	   50%	   decrease	   in	   STI1	   levels	   (Beraldo	   et	   al.,	   unpublished	   results).	   Neurons	  
were	  treated	  with	   increasing	  concentrations	  of	  Aβ	  oligomers	   (100	  nM,	  500	  nM,	  1	  μM,	  
and	  3	  μM).	  While	   treatment	  of	  wild	   type	  neurons	  with	   1	  μM	  Aβ	  oligomers	   showed	  a	  
tendency	  for	   increased	  cell	  death,	  there	  was	  no	  significant	  increase	  in	  cell	  death	  when	  
wild	   type	   neurons	   were	   treated	   with	   100	   nM	   to	   1	   uM	   Aβ	   oligomers	   (Figure	   4).	   In	  
contrast,	  neurons	  derived	   from	  STI1	  heterozygous	  knockout	  mice	   show	  significant	   cell	  
death	  at	   1	  μM	  Aβ	  oligomer	   treatment	   (Figure	  4).	  At	   a	  dose	  of	   500	  nM,	   STI1-­‐deficient	  
neurons	  also	  presented	  a	   tendency	   for	   increased	  cell	  death	   (Figure	  4).	   Interestingly,	   a	  
higher	  concentration	  of	  Aβ	  oligomers	  (3	  μM)	  caused	  similar	  levels	  of	  neuronal	  death	  on	  
neurons	  derived	   from	  both	  wild-­‐type	  and	  heterozygous	  STI1-­‐knockout	  mice.	  Together,	  
these	   data	   suggest	   that	   STI1	   deficiency	   increases	   sensitivity	   of	   these	   neurons	   to	   Aβ	  
oligomers.	  	  















4.4	   Extracellular	  STI1	  effect	  prevents	  Aβ	  oligomer-­‐induced	  neuronal	  death	  	  
To	  further	  test	  for	  a	  protective	  role	  of	  STI1,	  we	  investigated	  whether	  recombinant	  STI1	  
protein	  could	  prevent	  cell	  death	  induced	  by	  Aβ	  oligomers.	  In	  these	  experiments	  we	  used	  
1	  µM	  Aβ	  oligomers	  since	  we	  could	  see	  a	  small	  effect	  on	  wild-­‐type	  neurons	  and	  a	  large	  
effect	   on	   STI1	   mutants	   (Fig.	   5).	   Pre-­‐incubation	   with	   1	   μM	   recombinant	   STI1	   rescued	  
neurons	   derived	   from	  both	  wild	   type	   and	   STI1	   heterozygous	   knockout	  mice	   from	   the	  
toxicity	  of	   synthetic	  Aβ	  oligomers	   (Figure	  5&6A).	  Moreover,	  pre-­‐incubation	  with	  1	  μM	  
STI1∆	   230-­‐245,	   which	   lacks	   the	   PrPC	   binding	   site,	   still	   resulted	   in	   protection	   against	   Aβ	  
oligomers-­‐induced	   cell	   death	   on	   heterozygous	   STI1-­‐knockout	   neurons	   	   (Figure	   6A).	  
Treatment	   with	   synthetic	   1	   μM	   scrambled	   Aβ	   oligomers	   did	   not	   induce	   a	   significant	  
increase	   in	  cell	  death	   in	  either	  genotype	  (Figure	  6A).	  Treatment	  of	  neurons	  with	  3	  μM	  
Aβ	  oligomers	   induced	   cell	   death	   in	   neurons	  derived	   from	  wild-­‐type	   and	  heterozygous	  
STI1	  genotypes,	  and	   importantly,	   recombinant	  STI1	  protected	  both	  wild	   type	  and	  STI1	  
heterozygous	  neurons	  against	  this	  concentration	  of	  Aβ	  oligomers	  as	  well	  (Figure	  5&6B).	  
Overall,	  these	  data	  suggest	  that	  extracellular	  STI1	  can	  protect	  neurons	  against	  cell	  death	  
induced	   by	  Aβ	   oligomers,	   and	   it	   can	   also	   rescue	   the	   increased	   sensitivity	   to	   neuronal	  
death	  observed	  in	  STI1-­‐deficient	  neurons	  treated	  with	  Aβ	  peptides.	  	  
	  

















































































































5.1	   Neurotoxicity	  of	  Aβ	  Oligomers	  via	  the	  PrPC-­‐α7nAChR	  complex	  
5.1.1	  	   Aβ-­‐induced	  sustained	  Ca2+	  influx:	  dual	  dependence	  	  
According	  to	  our	  results,	  the	  presence	  of	  PrPC	  alone	  cannot	  initiate	  a	  cascade	  of	  events	  
leading	   to	   sustained	   Ca2+	   influx	   without	   α7nAChR	   following	   treatment	   with	   Aβ.	  
Sustained	   Ca2+	   influx	   might	   lead	   to	   disruption	   of	   Ca2+	   homeostasis	   and	   ultimately	   to	  
excitotoxicity	   and	   late	   cell	   death	   (Zundorf	  &	  Reiser,	   2011).	   PrPC	  was	   shown	   to	   require	  
the	  activity	  of	  α7nAChR	  to	  induce	  Ca2+	  influx	  and	  to	  induce	  signaling	  pathways	  (Beraldo	  
et	  al.,	  2010).	  Thus,	  we	  propose	  that	  PrPC	  might	  need	  to	  complex	  with	  α7nAChR	  to	  induce	  
sustained	  Ca2+	  influx.	  	  
Our	   results	  help	   to	  clarify	   the	  controversy	  concerning	   the	   role	  of	  α7nAChRs	  as	  an	  Aβ-­‐
binding	   partner.	   Some	   studies	   suggest	   that	   Aβ	   desensitizes	   (Dineley	   et	   al.,	   2002)	   or	  
blocks	   (Liu	   et	   al.,	   2001;	   Pettit	   et	   al.,	   2001;	   Tozaki	   et	   al.,	   2002)	   the	   α7nAChR.	   On	   the	  
contrary,	  other	  studies	  indicate	  that	  Aβ	  activates	  the	  α7nAChR	  (Dougherty	  et	  al.,	  2003;	  
Wang	  et	  al.,	  2003).	  The	  Aβ/α7nAChR	  controversy	  might	  be	  due	  to	  unsuspected	  roles	  of	  
other	   proteins	   involved	   in	   the	   interaction	   between	   Aβ	   and	   α7nAChR.	   	   As	  mentioned	  
previously,	  Dineley	   et	   al.,	   2002	   (Dineley	   et	   al.,	   2002)	   expressed	   rat	   α7nAChR	   alone	   in	  
Xenopus	  oocytes.	  Aβ	  directly	  induced	  current	  through	  the	  α7nAChR,	  but	  the	  Aβ-­‐induced	  
currents	  were	  unsustainable	  and	  the	  α7nAChR	  rapidly	  desensitized.	  Our	  results	  together	  





with	   Dineley	   et	   al.,	   2002	   (Dineley	   et	   al.,	   2002)	  might	   suggest	   that	   PrPC	  and	   α7nAChR	  
need	  to	  complex	  before	  mediating	  an	  Aβ-­‐induced	  sustained	  Ca2+	  signal.	   Indeed,	   it	  was	  
not	  until	  Dougherty	  et	  al.,	  2003	  (Dougherty	  et	  al.,	  2003)	  treated	  presynaptic	  terminals	  
isolated	  from	  wild	  type	  mice	  with	  Aβ	  that	  a	  sustained	  agonist-­‐like	  effect	  was	  observed.	  
The	  Aβ-­‐induced	   sustained	   Ca2+	   influx	   on	   presynaptic	   terminals	  might	   suggest	   that	   all	  
proteins	  needed	  for	  the	  Aβ-­‐induced	  influx	  were	  present,	  including	  PrPC.	  	  
Overall,	  these	  results	  suggest	  that	  Aβ	  might	  need	  PrPC	  to	  complex	  with	  the	  α7nAChR	  in	  
order	   to	   induce	   Ca2+	   influx	   and	   excitotoxicity.	   Therefore,	   I	   propose	   that	   the	   Aβ	  
dependence	   on	   PrPC	  and	   α7nAChR	   to	   induce	   sustained	   Ca2+	   influx	   to	   be	   partially	   the	  
reason	   why	   Aβ	   is	   dependent	   on	   PrPC	   (Kudo	   et	   al.,	   2012)	   and	   α7nAChR	   (Wang	   et	   al.,	  
2003)	  for	  neurotoxicity.	  Understanding	  what	  Aβ	  requires	  to	  induce	  sustained	  Ca2+	  influx	  
may	   give	   us	   insights	   into	   how	   to	   mitigate	   the	   neurotoxic	   effects	   of	   Aβ	   oligomers,	  
possibly	   by	   blocking	   interaction	   with	   PrPC	   and	   α7nAChR.	   However,	   it	   is	   important	   to	  
note	   that	   our	   results	   do	   not	   exclude	   other	   receptors	   or	   channels	   from	   being	   directly	  
responsible	  for	  the	  sustained	  Ca2+	  influx	  induced	  by	  Aβ.	  	  
	  
5.1.2	   The	  PrPC-­‐dependent	  Aβ-­‐induced	  neuronal	  death	  	  	  
Our	  data	  indicate	  that	  neuronal	  death	  induced	  by	  1μM	  Aβ	  was	  dependent	  on	  PrPC.	  PrPC	  
was	   shown	   to	   be	   a	   putative	   receptor	   for	   Aβ	   (Chen	   et	   al.,	   2010;	   Lauren	   et	   al.,	   2009).	  





Other	   studies	   also	   supported	   the	   deleterious	   effects	   of	   the	   proposed	   Aβ/PrPC	  
interaction	  on	  neuronal	  survival	  (Kudo	  et	  al.,	  2012;	  Resenberger,	  Harmeier,	  et	  al.,	  2011;	  
Resenberger,	   Winklhofer,	   &	   Tatzelt,	   2011;	   Resenberger	   et	   al.,	   2012).	   These	   studies	  
showed	  that	  overexpression	  of	  PrPC	  resulted	  in	  increased	  sensitivity	  from	  neurotoxicity	  
mediated	   by	   cell-­‐derived	   Aβ	   oligomers	   (Resenberger	   et	   al.,	   2012).	   Kudo	   et	   al.,	   2012	  
(Kudo	  et	  al.,	  2012)	  demonstrated	  that	  Aβ	   induced	  neuronal	  death	  via	  Aβ	  both	   in	  vitro	  
and	   in	   vivo	   using	   PrPC-­‐knockout	  mice.	   The	  mechanism	   by	  which	   Aβ	   induces	   neuronal	  
death	   is	   not	   well	   understood.	   Nonetheless,	   Aβ/PrPC	   interaction	  may	   compromise	   the	  
PrPC	  physiological	   functions.	  Thus,	  we	  need	  to	  have	  a	  good	  understanding	  of	   the	  PrPC-­‐
dependent	   physiological	   mechanisms	   to	   distinguish	   the	   manipulations	   caused	   by	   the	  
Aβ/PrPC	  interaction.	  	  
As	   previously	   mentioned,	   PrPC	   acts	   as	   a	   docking	   element	   on	   the	   cell	   membrane	   to	  
mediate	   interactions	  between	  multiple	  proteins	   (Martins	  &	  Brentani,	  2002;	  Martins	  et	  
al.,	   2002).	   PrPC	   mediates	   the	   effects	   of	   many	   ligands	   by	   initiating	   multiple	   signaling	  
pathways	   downstream	   of	   the	   binding	   at	   the	   cell	   surface.	   Aβ/PrPC	   interaction	   may	  
compromise	   the	   regulatory	   functions	   of	   PrPC	   by	   manipulating	   PrPC-­‐dependent	  
physiological	  signaling	  pathways.	  Moreover,	  the	  binding	  of	  Aβ	  to	  PrPC	  may	  also	   induce	  
different	   PrPC-­‐dependent	   signaling	   pathways	   that	   are	   not	   initiated	   under	   normal	  
physiological	  conditions.	  	  





Our	  data	  also	   indicate	  that	  neuronal	  death	  induced	  by	  3μM	  Aβ	  was	  not	  dependent	  on	  
PrPC	  for	   inducing	   neuronal	   death.	   At	   higher	   concentrations,	   Aβ	  may	   be	   utilizing	   other	  
mechanisms	  or	  proteins	  to	  induce	  neurotoxicity.	  Higher	  Aβ	  concentrations	  may	  result	  in	  
over-­‐activation	   of	   NMDARs,	   disruption	   of	   the	   lipid	   bilayer,	   or	   formation	   of	   reactive	  
oxygen	  species	  (Fandrich,	  2012)	  leading	  to	  neuronal	  death	  independently	  of	  PrPC.	  	  
	  
	  
5.2	   Synaptic	  protection	  and	  Neuroprotection	  of	  STI1	  via	  the	  PrPC-­‐α7nAChR	  complex	  
5.2.1	   STI1	  promotes	  neuronal	  survival	  	  	  
We	   tested	   the	   dependence	   of	   STI1-­‐induced	   Ca2+	   influx	   on	   α7nAChR	   using	   α7nAChR-­‐
knockout	  hippocampal	  primary	  culture	  neurons.	  Our	  data	  provided	  evidence	  that	  STI1	  
required	  α7nAChR	  to	   induce	  Ca2+	   influx	   in	  neurons.	   In	  Beraldo	  et	  al.,	  2010	   (Beraldo	  et	  
al.,	  2010),	  it	  was	  shown	  that	  STI1	  required	  both	  the	  presence	  of	  PrPC	  and	  the	  activity	  of	  
the	  α7nAChR	  to	  induce	  protection	  against	  cellular	  insults	  like	  Staurosporine.	  Moreover,	  
STI1	   induced	   protection	   of	   neurons	   in	   a	   PrPC-­‐dependent	   fashion	   in	   other	   studies	  
(Chiarini	   et	   al.,	   2002;	   Lopes	   et	   al.,	   2005;	   Zanata	   et	   al.,	   2002).	   Thus,	   the	   effect	   of	   STI1	  
seems	   to	  be	  dependent	  on	   the	   scaffolding	  property	  of	  PrPC	   and	  on	   the	   transient	  Ca2+	  
permeability	  of	  the	  α7nAChR	  to	  induce	  protection	  of	  neurons.	  	  






5.2.2	   Decreased	  levels	  of	  STI1	  increase	  the	  sensitivity	  of	  neurons	  to	  Aβ	  	  
The	   dependence	   of	   STI1	   and	   Aβ	   on	   the	   PrPC-­‐α7nAChR	   complex	  might	   result	   in	   direct	  
competition	  between	   STI1	   and	  Aβ	   for	   the	  PrPC-­‐α7nAChR	   complex.	   Indeed,	   our	   results	  
suggested	   that	   lack	   of	   STI1	   increased	   the	   sensitivity	   of	   neurons	   to	   Aβ.	   Also,	   it	   was	  
already	   shown	   in	   unpublished	   results	   that	   recombinant	   STI1	   competes	   with	   Aβ	   for	  
binding	   to	   PrPC	  (Beraldo	   et	   al.,	   unpublished).	   The	   potential	   competition	   between	   STI1	  
and	  Aβ	   is	  also	   supported	  by	   the	  close	  proximity	  of	   the	  binding	   sites	  of	  STI1	   (113-­‐128)	  
(Zanata	   et	   al.,	   2002)	   and	   Aβ	   (95-­‐110)	   (Lauren	   et	   al.,	   2009)	   on	   PrPC.	   The	   direct	  
competition	  between	  STI1	  and	  Aβ	  might	  mean	  that	  the	  PrPC-­‐α7nAChR	  complex	  may	  be	  
used	  as	  a	  therapeutic	  target	  in	  AD.	  
	  As	   previously	   stated,	   our	   laboratory	   showed	   that	   there	   is	   a	   decrease	   in	   STI1	   protein	  
levels	   in	   6-­‐month-­‐old	   APPSwe/PS1dE9	   mice	   (unpublished	   observations).	  
APPSwe/PS1dE9	  mice,	   an	  AD	  animal	  model,	   show	  plaque	   formation,	   synapse	   loss	  and	  
behavioral	  deficits	  (Games	  et	  al.,	  1995;	  Lesne	  et	  al.,	  2006;	  Mucke	  et	  al.,	  2000).	  	  Although	  
the	   role	   of	   STI1	   in	   AD	   is	   not	   known,	   I	   hypothesized	   that	   changed	   STI1	   levels	   may	  
contribute	   in	   part	   of	   the	   pathology	   observed	   on	   the	   APPSwe/PS1dE9	  mice.	   Our	   data	  
using	  neurons	  derived	  from	  heterozygous	  STI	  knockout	  mice	  supported	  this	  hypothesis.	  
Lack	  of	   STI1	   seems	   to	   increase	   sensitivity	  of	   neurons	   to	  Aβ	  oligomers.	   Therefore,	   it	   is	  





important	   to	   elucidate	   the	   mechanism	   by	   which	   lack	   of	   endogenous	   STI1	   leads	   to	  
increased	  sensitivity	  from	  Aβ.	  	  
	  
5.2.3	   STI1	  protects	  against	  Aβ	  neurotoxicity	  	  
Interestingly,	  the	  addition	  of	  recombinant	  STI1	  rescued	  neurons	  derived	  from	  both	  wild-­‐	  
type	   and	   heterozygous	   STI1-­‐knockout	   mice	   against	   Aβ-­‐induced	   neurotoxicity.	   Our	  
findings	   suggested	   that	   STI1	   might	   not	   protect	   neurons	   through	   a	   mechanism	   fully	  
dependent	   on	   PrPC,	   as	   treatment	   with	   STI1Δ230-­‐245	   still	   resulted	   in	   protection.	  
Nonetheless,	  unpublished	  data	  revealed	  that	  STI1	  was	  able	  to	  rescue	  the	  synaptotoxic	  
effects	   of	   Aβ	   in	   a	   PrPC-­‐dependent	   fashion	   by	   mainting	   the	   levels	   of	   synaptophysin	  
protein	  (Hajj	  et	  al.,	  unpublished).	  The	  PrPC-­‐dependence	  of	  the	  synapto-­‐protective	  effect	  
of	   STI1	   against	   Aβ	  was	   tested	   on	   PrPC-­‐knockout	   neurons.	   Thus,	   the	   different	  ways	   of	  
assessing	  PrPC	  dependency	  may	  be	  the	  reason	  why	  STI1	  was	  not	  fully	  dependent	  on	  PrPC	  
to	  protect	  neurons	  in	  our	  experiments.	  Furthermore,	  STI1	  was	  able	  to	  rescue	  against	  Aβ-­‐
induced	  50%	  drop	  in	  LTP	  (Beraldo	  et	  al.,	  unpublished).	  Thus,	  there	  is	  mounting	  evidence	  
linking	  the	  STI1-­‐PrPC	  complex	  to	  the	  synapse.	  
	  It	   is	   known	   that	   STI1	   is	   involved	   in	   promoting	   neuritogenesis	   in	   a	   PrPC-­‐dependent	  
fashion	  by	   inducing	  ERK	  1/2	  phosphorylation	   (Lopes	  et	  al.,	   2005).	  Beraldo	  et	  al.,	   2010	  
showed	   that	   the	   STI1-­‐induced	   ERK	   1l2	   phosphorylation	   is	   dependent	   on	   PrPC	  and	   the	  





activity	  of	  the	  α7nAChR.	  Further,	  α7nAChR	  is	  thought	  to	  be	  an	  important	  modulator	  of	  
glutamatergic	  synapses	  (Lozada	  et	  al.,	  2012).	  Thus,	  the	  role	  of	  STI1	  may	  be	  important	  in	  
synapse	  formation	  by	  promoting	  neurite	  growth	  through	  the	  α7nAChR,	  and	  possibly	  in	  
synaptic	  function	  by	  modulating	  the	  PrPC-­‐α7nAChR	  complex	  at	  the	  synapse.	  	  
Therefore,	   our	   results	   and	   previous	   data	   from	  others	   suggest	   that	   PrPC	   and	  α7nAChR	  
may	   be	   involved	   in	   the	   STI1-­‐induced	   synapto-­‐protective	   effects	   (Hajj	   et	   al.,	  
unpublished).	  Thus,	  I	  speculate	  that	  STI1	  protection	  against	  the	  Aβ-­‐induced	  disruption	  of	  
synaptic	   plasticity	   may	   be	   the	   basis	   of	   the	   STI1	   protection	   against	   the	   Aβ-­‐induced	  
neuronal	  death	  we	  observed.	  More	  specifically,	  I	  hypothesize	  that	  after	  formation	  of	  the	  
STI1-­‐PrPC	  complex,	  which	  prevents	   the	  binding	  of	  Aβ	   to	  PrPC	  (Figure	  7,	  Model	  A),	  PrPC	  
recruits	  the	  α7nAChR.	  As	  a	  complex,	  I	  speculate	  that	  PrPC	  and	  the	  α7nAChR	  regulate	  the	  
synapse	  through	  controlled	  Ca2+	  influx	  (Figure	  7,	  Model	  B).	  The	  proper	  regulation	  of	  the	  
synapse	  may	   prevent	   the	   PrPC-­‐dependent	   Aβ-­‐induced	   synaptotoxic	   effects	   (Lauren	   et	  
al.,	  2009)	  and	  the	  neuronal	  death	  we	  observed.	  	  	  
On	  the	  other	  hand,	  the	  binding	  of	  Aβ	  to	  PrPC,	  in	  the	  presence	  of	  less	  STI1,	  may	  result	  in	  
the	   recruitment	  of	  α7nAChR.	   Consequently,	  Aβ	  might	   change	  physiological	   Ca2+	   influx	  
through	   the	   α7nAChR	   (Figure	   7,	   Model	   C).	   The	   potential	   PrPC-­‐α7nAChR	   complex	  
regulation	   of	   the	   synapse	   may	   become	   compromised.	   Ultimately,	   the	   neuron	   will	  
degenerate	   due	   to	   disruption	   of	   synaptic	   transmission	   leading	   to	   the	   neuronal	  
degenerative	  phenotype	  observed	  in	  AD.	  	  





Confirmatory	   experiments	   can	   be	   done	   on	   mice	   produced	   from	   the	   breeding	   of	  
heterozygous	  STI1	  knockout	  and	  the	  APPSwe/PS1dE9	  mice.	  The	  offspring	  will	  have	  less	  
STI1	   and	   develop	   amyloidosis	   and	   behavioral	   deficits	   concurrently.	   I	   would	   speculate	  
that	   reduced	   levels	   of	   STI1	   could	   affect	   the	   development	   of	   amyloidosis	   in	   vivo.	  
Although	   the	   putative	   mechanism	   we	   proposed	   for	   the	   effects	   of	   STI1	   involves	   a	  
competition	   with	   Aβ	   oligomers,	   it	   is	   important	   to	   evaluate	   if	   changes	   in	   STI1	   levels	  
would	  affect	  the	  generation	  of	  Aβ	  peptides	  or	  plaque	  formation.	  Spatial	  memory,	  which	  
is	  associated	  with	  hippocampal	  function,	  can	  also	  be	  evaluated	  in	  order	  to	  investigate	  if	  
decreased	  STI1	  levels	  can	  escalate	  the	  behavioral	  deficits	  in	  aged	  APPSwe/PS1dE9	  mice.	  
We	  would	   expect,	   based	   on	   our	   results,	   that	   the	   double	   transgenic	  mice	  would	   have	  



























We	  hypothesized	   that	   STI1	   can	  protect	   against	  Aβ-­‐induced	  neurotoxicity	   via	   the	  PrPC-­‐
α7nAChR.	   The	   dependence	   of	   STI1	   on	   the	   PrPC-­‐α7nAChR	   for	   Ca2+	   influx	   and	   for	  
neurotrophic	   actions,	   and	   the	   PrPC	   dependence	   of	   Aβ	   for	   neurotoxicity	   comprised	  
rationale	   for	   this	   hypothesis.	   Although	  we	   showed	   that	   Aβ	   is	   dependent	   on	   PrPC	   and	  
α7nAChR	  for	  sustained	  Ca2+	  influx,	  we	  did	  not	  test	   the	  dependence	  of	  Aβ	  on	  α7nAChR	  
for	   inducing	   neuronal	   death.	   If	   Aβ	   was	   found	   to	   be	   dependent	   on	   α7nAChR	   for	   cell	  
death,	  then	  the	  Aβ-­‐PrPC-­‐α7nAChR	  complex	  could	  be	  linked	  to	  sustained	  Ca2+	  influx	  and	  
Aβ-­‐induced	   cell	   death.	   If	   confirmed,	   the	   dependency	   of	   Aβ	   on	   α7nAChR	   would	   also	  
strengthen	   our	   proposed	   link	   between	   sustained	   Ca2+	   influx,	   as	   a	   source	   of	  
excitotoxicity,	   and	   neuronal	   death.	   Also,	   we	   think	   that	   it	   is	   important	   to	   preincubate	  
wild	  type	  neurons	  with	  STI1	  and	  assess	  if	  STI1	  can	  prevent	  the	  sustained	  Ca2+	  influx	  after	  
treatment	  with	  Aβ.	  If	  STI1	  prevented	  the	  sustained	  Ca2+	  influx,	  we	  can	  then	  use	  STI1	  in	  
combination	  with	  PrPC	  antibodies	  and	  α7nAChR	  blockers	  to	  test	  if	  STI1	  needs	  either	  PrPC	  
or	  α7nAChR	  for	  prevention	  of	  Aβ-­‐induced	  sustained	  Ca2+	  influx.	  	  
It	  would	  be	  interesting	  to	  test	  if	  STI1	  can	  protect	  PrPC-­‐knockout	  and	  α7nAChR-­‐knockout	  
neurons	  against	  Aβ-­‐induced	  neuronal	  death	  by	  using	  the	  same	  cell	  death	  assay	  used	  in	  
this	  study.	  If	  STI1	  did	  not	  protect	  PrPC-­‐knockout	  and	  α7nAChR-­‐knockout	  neurons	  against	  
Aβ-­‐induced	  neuron	  death,	  then	  STI1	  may	  require	  the	  presence	  of	  PrPC	  and	  α7nAChR	  to	  
protect	  against	  Aβ.	  	  





As	  mentioned	  previously,	   it	  was	  reported	  that	  knocking	  out	  PrPC	  or	  α7nAChR	  from	  AD	  
mouse	  models	   alleviated	   the	   behavioral	   and	   synaptic	   dysfunctions	   observed	  on	   these	  
mice	  (Dziewczapolski	  et	  al.,	  2009;	  Gimbel	  et	  al.,	  2010).	  Thus,	  it	  would	  be	  very	  important	  
and	   confirmatory	   to	  our	   studies	   to	   assess	   synaptic	  plasticity	  on	  neurons	  derived	   from	  
APP/α7KO	   and	   APP/PrPCKO	   mice	   after	   preincubation	   with	   STI1.	   It	   has	   already	   been	  
shown	  that	  STI1	  protects	  against	  Aβ	  synaptotoxicity	  in	  a	  PrPC-­‐dependent	  fashion	  (Hajj	  et	  
al.,	  unpublished).	  We	  can	   further	  assess	  synaptic	  structure	  by	  quantifying	  the	  synaptic	  
marker,	   synaptophysin,	   on	   synapses	   derived	   from	   α7nAChR-­‐knockout	   embryos	   after	  
pre-­‐incubation	  with	  STI1	  and	  treatment	  with	  Aβ.	  	  
To	   test	   if	  NMDARs	  are	  directly	   responsible	   for	   the	  sustained	  Ca2+	  influx	  observed	  after	  
treatments	  with	  Aβ,	  we	  can	  assess	  Ca2+	  influx	  in	  wild	  type,	  PrPC	  knockout	  and	  α7nAChR-­‐
knockout	   neurons	   after	   pre-­‐incubation	   with	   an	   NMDAR	   selective	   antagonist	   and	  
treatment	  with	  Aβ.	   If	  the	  NMDAR	  antagonist	  prevented	  the	  Aβ-­‐induced	  sustained	  Ca2+	  
influx	  then	  NMDARs	  might	  be	  responsible	  for	  the	  sustained	  Ca2+influx.	  Also,	  we	  can	  use	  
the	   NMDAR	   antagonist	   on	   with	   the	   cell	   death	   assays	   we	   used.	  We	   can	   pre-­‐incubate	  
PrPC-­‐knockout	  and	  α7nAChR-­‐knockout	  neurons	  with	  the	  NMDAR	  antagonist	  and	  test	  for	  
Aβ-­‐induced	   cell	   death.	   Testing	   the	   effect	   of	   NMDAR	   antagonism	   on	   Aβ-­‐induced	  
sustained	   Ca2+	   and	   neuron	   death	   can	   give	   us	   better	   understanding	   of	   the	   role	   of	  
NMDARs	  in	  Aβ-­‐induced	  excitotoxicity.	  
	  












































Our	   results	   suggest	   that	   Aβ	  may	   utilize	   the	   PrPC-­‐α7nAChR	   complex	   for	   sustained	   Ca2+	  
influx.	   The	   Aβ-­‐mediated	   sustained	   Ca2+	   influx	   might	   be	   the	   start	   of	   a	   pathological	  
signaling	   cascade	   leading	   to	   our	   second	   observation,	   the	   Aβ-­‐mediated	   and	   PrPC-­‐
dependent	   neuronal	   cell	   death.	   In	   addition,	   we	   tested	   whether	   STI1,	   a	   PrPC	   ligand	  
proposed	  to	  utilize	   the	  PrPC-­‐α7nAChR	  complex	   for	  neuroprotection,	   requires	  α7nAChR	  
for	   induction	   of	   Ca2+	   influx.	  We	   tested	   the	   dependence	   of	   STI1	   on	   α7nAChR	   for	   Ca2+	  
influx	  using	  α7nAChR-­‐knockout	  hippocampal	  neurons	  and	  found	  that	  STI1	  required	  the	  
presence	   of	   α7nAChR	   to	   induce	   Ca2+	   influx.	   Moreover,	   we	   tested	   if	   STI1	   can	   protect	  
against	   Aβ-­‐mediated	   neuronal	   cell	   death.	   Neurons	   derived	   from	   a	   mouse	   model	  
expressing	  half	  the	  level	  of	  STI1	  (STI1	  KO/WT)	  compared	  to	  wild	  type	  showed	  increased	  
sensitivity	  to	  Aβ	  than	  their	  wild	  type	  counterparts.	  Furthermore,	  the	  treatment	  of	  STI1	  
KO/WT	  and	  wild	  type	  neurons	  with	  recombinant	  STI1	  rescued	  STI1	  KO/WT	  and	  wild	  type	  
neurons	  against	  the	  Aβ-­‐induced	  cell	  death.	  	  
In	  conclusion,	  our	  results	  suggest	  that	  the	  PrPC-­‐α7nAChR	  complex	  may	  be	  an	  important	  
mediator	  of	  Aβ-­‐induced	  pathology	  in	  AD.	  Therefore,	  this	  complex	  may	  be	  an	  important	  
therapeutic	   target	   in	   AD.	   We	   also	   identified	   a	   protein	   that	   may	   be	   important	   in	   a	  
physiological	   protective	  mechanism.	   STI1	  may	   able	   to	   protect	   the	   synapse	   against	   Aβ	  
and	  as	  such	  result	  in	  amelioration	  of	  AD-­‐related	  behavioral	  deficits.	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Experimental ←Use Experimental Group  ID # (column directly left) to 





Group ID #   
 
  
assign group to details in Sections F & G, 




















Group ID #  
←Assign sequential Group ID # (column directly left). Use 
ID# in Sections F & G, right hand column 
Name of 
Experimental 
Group  &/or 
Species or Strain 
 
Total Animal 













Group ID #  
←Assign sequential Group ID # (column directly left). Use 
ID# in Sections F & G, right hand column 







Group  &/or 

















Group ID #  
←Assign sequential Group ID # (column directly left). Use 
ID# in Sections F & G, right hand column 
Name of 
Experimental 
Group  &/or 
Species or Strain 
 
Total Animal 













Group ID #   
  
←Use Experimental Group  ID # (column directly left) to 
assign group to details in Sections F & G, 
 right hand column 

























Group ID #  
←Assign sequential Group ID # (column directly left). Use 
ID# in Sections F & G, right hand column 
Name of 
Experimental 
Group  &/or 
Species or Strain 
 
Total Animal 













Group ID #  
←Assign sequential Group ID # (column directly left). Use 
ID# in Sections F & G, right hand column 
Name of 
Experimental 
Group  &/or 
Species or Strain 
 




















Group ID #  
←Assign sequential Group ID # (column directly left). Use 
ID# in Sections F & G, right hand column 
Name of 
Experimental 
Group  &/or 
Species or Strain 
 
Total Animal 













Group ID #   
  
←Use Experimental Group  ID # (column directly left) to 
assign group to details in Sections F & G, 




Species or Strain 
 




















F.  EXPERIMENTAL DETAILS - Mandatory Completion Required 
Using the groups you have indicated in Section E., provide 
details of all experiments, events & procedures involving 
animals in each of the groups. 
 Use the right-hand column to connect the ‘event’ with the 
specific group(s) identified in Section E. 














“In experiments involving animals, any actual or potential pain, distress, or 
discomfort should be minimized or alleviated by choosing the earliest 
endpoint that is compatible with the scientific objectives of the research.  
Selection of this endpoint by the investigator should involve consultation with 
the lab animal vet and the animal care committee.” CCAC General Guideline 






If mutant mice develop severe neurological symptoms and 
loss of weight they will be euthanized shortly after symptoms 
appear.  
Adult mice that have had stereotaxic surgery will be initially 
monitored according to Standard Operating Procedure # 321-02 
 All  
Or  
 ID #s 
 





(CRITERIA FOR EARLY EUTHANASIA / RODENTS). If any 
suspicious condition is observed the ACVS veterinary service is 
going to be called to examine the animal and assess the 
necessity for early euthanasia. After behavioral studies these 
mice are going to be euthanized with CO2 to obtain tissues for 




Pick all that will be followed 
 #320 Euthanasia  
 #321-Criteria for Early 
Euthanasia-Rodents 
 #322-Criteria for Early 
Euthanasia-Non-Rodents 




 ID #s 
 
 





Pick All Euthanasia Methods That Will Be Followed & Provide 
Euthanasia Related Agent Use Detail Below 
 Animals Not 
Euthanized 
 Barbiturate Overdose 
 CO2 
 Decapitation under 
Anaesthesia 
 *Decapitation with No 
Anaesthesia* 
 Cervical Dislocation 
with Anaesthesia 
 *Cervical Dislocation 
with No Anaesthesia* 
 Other Method(s), 
Anaesthetized - explain 
 *Other Method(s), 












  ID #s 
 



















 All  
Or  






Describe how animals will be ‘disposed of’ if not euthanized 
Animals that are not going to be used in our experiments (extra 
mice) are going to be offered to other scientists for their 
use.  
 All  
Or  






WT mice euthanized via CO2 will be made available to the Wild Life 
Rehabilitation Centre for feeding. 
 
 
























 No Agent Use (Go to F 3.) 




















IP 1ml/kg As 





 As Above   Click Here   
 
As Above   Click Here   
 Yes 
 No 
 All  
or 
ID #s 
As Above   Click Here   








As Above   Click Here   
 Yes 
 No 









As Above   Click Here   
 Yes 
 No 















IP 1 ml/kg As needed  Yes  
 No 




























   Yes   No 









As Above   Click Here   
 Yes 
 No 
 All  
or 
ID #s 
As Above   Click Here   
















Mouse  IP   
 Yes 
 No 




As Above   Click Here   
 
Mouse  IP   
 Yes 
 No 




As Above   Click Here   
 
Mouse  IP   
 Yes 
 No 




As Above   Click Here   
 
Mouse  Other, detail below   
 Yes 
 No 




As Above   Click Here   
HAZARDOUS AGENTS – Complete Below Section AND Section 




































Animal Biosafety L.1  
Category 
Mouse  Other, detail below    Yes  No 
 All 
Or  ID 
#s 



















Has this cell line/biological agent been tested for murine 
pathogens?     Yes    No 







As Above   Click Here   
 Yes 
 No 
 All  
Or  ID 
#s 
 
Has this cell line/biological agent been tested for murine 
pathogens?     Yes    No 



















As Above   Click Here   
 Yes 
 No 











As Above   Click Here   
 Yes 
 No 









As Above   Click Here   
 Yes 
 No 




As Above   Click Here   














Controled drugs such as cocaine are going to be stored in a 2 lock 
system. The cocaine will be in a locked box inside of a locked cabinet. 
Both keys will be kept in a separate room and will be unlabelled. We are 
going to keep a log sheet which will record date, amount taken, amount 
left, animal species and ID, and the signature of user. MSDS for all 
controled drugs will be kept in a binder close to the drug cabinet. 
 
 















 Yes  
 No If Yes, provide justification & duration detail  
 All  
or 





Care Person(s)  Contact #  
 All  
or 
 ID #s 
 
SOPs Pick all that will be followed  








Anaesthetic Care-Level 1 
 332-Post-operative/Post-
Anaesthetic Care-Level 2 
 333-Post-operative/Post-
Anaesthetic Care-Level 3 
 334-Post-operative/Post-






 Other, please explain  
 
 
 All  
or 














approved area.  If clicked, 
provide scientific justification: 
 
 All  
or 










When will animals be 
returned  
to the main facility? Surgery 
will be performed early in the 
morning and mice are going to be 
monitored during the day 
according to SOP 321-02 
(CRITERIA FOR EARLY 




RODENTS). If everything is OK 
mice are going to be returned to 
the main facility at the end of the 
day 
 All  
or 












F. 4. Antibody Production 
 No Antibody Production (Go to F.5.) 
 
F. 5. Monitoring or Chronic Projects – i.e. Post-op, Feed, 















Pick all that will be followed 
 100-Monitoring/Tumour Growth in Rodents 
 310-Holding Period Post Admission  
 Other,  please explain  
 
 






 Weight   Food Intake  Behaviour  Urine Output  
Other, explain   








Pick all that apply to this 
project:  
 Hourly    Twice Daily   
 Daily   
 Weekly  Other, 
please explain 
If other, or multiple frequencies 
chosen, please provide detail:   
Weight, food and water intake, 
appearance and behavior are 
monitored post op (SOP 321-02 
and SOP 330-03) or daily for 
experimental purposes. 






Care Person(s)  Contact #    All  














Will animal monitoring 
records be kept with the 
animal? 
 Yes or   No 
If ‘No’, identify monitoring 
record location 
  










F. 6  Breeding  
 No breeding elements (Go to F.7) 
I. Indicate Breeding Type   
 Breeding for research within this protocol   
 Breeding for research NOT within this protocol 
Complete for All Breeding Elements 
II. Provide justification for 
maintaining a breeding colony 
 
III. Provide justification for 
breeding numbers 
Quote animal  numbers within 
Section G. Animal 
Requirements 
 
IV. List procedures used in the 
breeding colony 
 
V. Number estimation and use 
of surplus animals ( those not 
required for experimental 
Surplus Number Estimate:  
Surplus Use: -Animals that are not going to be used in 
our experiments (extra mice) are going to be offered to 





programs, or retired breeders) other scientists for their use. 
- WT mice euthanized via CO2 will be made available to 
the Wild Life Rehabilitation Centre for feeding 
 
VI. Breeding colony location, if 




VII. Research associates 
directly involved in the care of 
animals in this breeding 
colony 
Name:    Contact #:   Email:  
Name:    Contact #:   Email:  
Breeding for External Protocols Only 
VIII. List External Protocol 
Researcher(s)  
                   
IX. List External Protocol 
Numbers 
                               
 
F. 7. Blood Collection Identify 
Section E. 
Experimental 
Group ID #s 
Involving  
This Element 
 No Blood Collection (Go to F.8.) 
 
F. 8  Genetically Altered Animal Information 
 No Genetically Altered Animals Used (Go to F. 9.) 
i.  Gene Name      





ii. Has this animal 
already been 
generated? 
 Yes   
No 
 Yes   
No 
 Yes   
No 
 Yes  
 No 
 Yes   
No 
iii. If yes to ii., by 
which institution? 
 
     
iv. Is the animal 
commercially 
available? 
 Yes   
No 
 Yes   
No 
 Yes   
No 
 Yes  
 No 
 Yes   
No 
v.  If yes to iv. insert 
vendor strain 
information URL, 
then proceed to 
Sect. G 
     


































Complete details separately for hetero and homozygous animals 
Detail how this alteration affects the animal’s quality of life, 






     




































F. 8  Genetically Altered Animal Information 
 No Genetically Altered Animals Used (Go to F. 9.) 
i.  Gene Name      
ii. Has this animal 
already been 
generated? 
 Yes   
No 
 Yes   
No 
 Yes   
No 
 Yes  
 No 
 Yes   
No 
iii. If yes to ii., by 
which institution? 
     
iv. Is the animal  Yes    Yes    Yes    Yes   Yes   







No No No  No No 
v.  If yes to iv. insert 
vendor strain 
information URL, 
then proceed to 
Sect. G 
 
     






















     
Phenoty
pe 
Complete details separately for hetero and homozygous animals 
Detail how this alteration affects the animal’s quality of life, 















     



























F. 9. Procedural Description - Mandatory Completion for All Projects 
Minus the details presented in Sections 1 to 5, 
provide a concise description of the procedural events 
experienced by the animals in each experiment.   
The intent is to order, name and briefly describe the procedural 
events that animals of each experimental cohort will experience. 
The events should be presented numerically in chronological 
number. 
Evaluate the potential to cause pain and indicate the experimental 
groups experiencing each procedural event. 






































 All  
or 
 





 All  
or 
 









Mice are anaesthetized and placed into a 
stereotaxic apparatus (Kopf). A single scalp 
incision is made. A burr hole (approximately 3 
mm in diameter) is made in the skull and a glass 
micro pipette filled with 1 microliter of  AAV-Cre 
is going to be stereotaxically microinjected into a 
specific brain area. Only one area of the brain 
will be injected in each animal. To minimize 
tissue injury,these injections are going to be 
performed using glass pipettes with a 10- to 20-
micrometer diameter tip, and AAV-Cre is going 
to be  slowly injected over 1 hr using a pressure-
injection system. After an additional period of 5 
minutes, the micropipette is removed and the 
scalp incision is closed with wound clips. Sham 





 All  
or 
 





except that the pipette will be filled with vehicle, 
and no injection will be made. Animals are kept 
on heat pads or under heat lamps to maintain 
body temperature throughout the procedures. 
During recovery, animals are kept in the surgery 
room to allow frequent monitoring of breathing 
and general activity (according to SOP330-03 
POST-OPERATIVE/POST ANAESTHETIC CARE 
RODENTS) before being transported back to the 
holding room. The procedure is going to be 
performed once in each animal and we will use 













G. ANIMAL REQUIREMENTS - Mandatory Completion Required 
Detail all animal requirements including, species, strain, 
age/weight, sex, housing, dietary and animal total details for 
the Upcoming Year Only 
*Use bottom row of this section to add more detail to any column*  
Researcher must provide scientific justification for overnight animal housing in non-
approved areas, i.e. labs, & receive AUS approval:   
Use Section F. 3 for surgery related housing & bottom of this section  for all other 
housing justification  






























See Drop-downs for complete listing 
Abbreviations:     
CBM=Centre for Brain & Mind          HSACF=Health 
Sciences Animal Care Facility 
LHRI=Lawson Health Research Institute, St. Joe’s 
LHSC-UC=University Campus  LHSC-SS=South 
Street 
LHSC-VRL=Victoria Research Lab  LRCC=London 
Regional Cancer Centre 
RACF= Robarts Barrier Facility  REB= Robarts 
Experimental Barrier  











































































M/F HSACF Same as Housing 
 
 




M/F HSACF Same as Housing 
 
 




Male HSACF Same as Housing 
 
 
Yes   









Female HSACF Same as Housing 
 
 




Male HSACF Same as Housing 
 
 




Female HSACF Same as Housing 
 
 




Male HSACF Same as Housing 
 
 




Female HSACF Same as Housing  
 




Male HSACF Same as Housing 
 
 




Female HSACF Same as Housing  
 
 




Male HSACF Same as Housing 
 
 




Female HSACF Same as Housing 
 
 




Male HSACF Same as Housing 
 
 




Female HSACF Same as Housing 
 
 




Male HSACF Same as Housing 
 
 




Female HSACF Same as Housing 
 
 
Yes   
Mouse 
 
 Male HSACF Same as Housing  
 
Yes   
Mouse 
 
 Female HSACF Same as Housing  
 
Yes   









Male HSACF Same as Housing 
 
 




Female HSACF Same as Housing 
 
 




M/F HSACF Same as Housing   
 




Male HSACF Same as Housing  
 
 




Female HSACF Same as Housing  
 
 




Male HSACF Same as Housing  
 
 




Female HSACF Same as Housing  
 
 
Yes   
Mouse  
 

























Male HSACF Same as Housing   
 




Female HSACF Same as Housing   
 




Male HSACF Same as Housing   
 




Female HSACF Same as Housing   
 
Yes   









Male HSACF Same as Housing  
 
 




Female HSACF Same as Housing  
 
 




M/F HSACF Same as Housing   
 




M/F HSACF Same as Housing   
 




Male HSACF Same as Housing  
 
 




Female HSACF Same as Housing  
 
 
No   
Mouse 
 
 Male HSACF Same as Housing   
 
Yes   
Mouse 
 
 Female HSACF Same as Housing   
 
Yes   
Mouse 
 
 Male HSACF Same as Housing   
 
Yes   
Mouse 
 
 Female HSACF Same as Housing   
 
Yes   
Mouse 
 
 Male HSACF Same as Housing   
 
Yes   
Mouse 
 
 Female HSACF Same as Housing   
 
Yes   
Mouse 
 
 Male HSACF Same as Housing   
 




Female HSACF Same as Housing   
 




Male HSACF Same as Housing   
 
Yes   









Female HSACF Same as Housing  
 
 




Male HSACF Same as Housing  
 
 




Female HSACF Same as Housing  
 
 




Male HSACF Same as Housing  
 
 




Female HSACF Same as Housing  
 
 




Male HSACF Same as Housing  
 
 




Female HSACF Same as Housing  
 
 




Male HSACF Same as Housing  
 
 
Yes   
Mouse 
 
 Female HSACF Same as Housing   
 
Yes   
Mouse 
 
 Male HSACF Same as Housing   
 
Yes   
Mouse 
 
 Female HSACF Same as Housing   
 
Yes   
Mouse 
 
 Male HSACF Same as Housing   
 
Yes   
Mouse 
 
 Female HSACF Same as Housing   
 
Yes   
Mouse 
 
 Male HSACF Same as Housing   
 




Female HSACF Same as Housing   
 
Yes   









Male HSACF Same as Housing  
 
 




Female HSACF Same as Housing  
 
 




Male HSACF Same as Housing  
 
 




Female HSACF Same as Housing  
 
 




Male HSACF Same as Housing  
 
 




Female HSACF Same as Housing  
 
 




Male HSACF Same as Housing  
 
 




Female HSACF Same as Housing  
 
 
Yes   
Mouse 
 
 Male HSACF Same as Housing   
 
Yes   
Mouse 
 
 Female HSACF Same as Housing   
 
Yes   
Mouse 
 
 Male HSACF Same as Housing   
 
Yes   
Mouse 
 
 Female HSACF Same as Housing   
 
Yes   
Mouse 
 
 Male HSACF Same as Housing   
 
Yes   
Mouse 
 
 Female HSACF Same as Housing   
 




Male HSACF Same as Housing   
 
Yes   









Female HSACF Same as Housing  
 
 




Male HSACF Same as Housing  
 
 




Female HSACF Same as Housing  
 
 




M/F HSACF Same as Housing  
 
 





































We	  intend	  to	  house	  some	  of	  the	  breeding	  pairs	  at	  the	  Robarts	  Barrier	  
Facility	  for	  precautionary	  measures,	  since	  the	  genetically	  modified	  animals	  
are	  unique	  and	  we	  are	  the	  only	  researchers	  in	  the	  world	  that	  have	  them.	  	  
Some	  of	  the	  mice	  kept	  at	  ACVS	  will	  be	  transferred	  to	  Robarts	  for	  behavioral	  
studies.	  They	  will	  be	  transported	  in	  cages	  covered	  either	  with	  garbage	  bags	  
or	  cloth	  covers,	  water	  bottles	  are	  going	  to	  be	  turned	  right	  side	  up	  to	  prevent	  
flooding	  during	  transport	  and	  returned	  to	  its	  original	  down	  position	  once	  in	  
the	  proper	  holding	  room 
 
H. ADDENDA 
Addendum  1 –  No Teaching Elements 







 Addendum  2 – 
Wildlife Study ONLY  No Wildlife Study Elements 
1.1.1  
Addendum 3 - Hazardous &/or Biological Agent Use  ONLY – 
Occupational Health and Safety 
 No Hazardous &/or Biological Agent Use 
University of Western Ontario  
Animal Use Protocol Safety 
Form 
For further information, please contact J. 
Stanley - jstanle2@uwo.ca 
1.1.2 Protocol Title:  
 
 
 Approved:  June 10, 2003             
OHS Use Only 
Permit Number Issued:  We	  have	  
submitted	  the	  application	  forms	  to	  the	  
biosafety	  committee	  and	  are	  waiting	  for	  their	  
approval. 
Schedule I   Work with Biological Organisms 
1.1  List microorganisms that will be used in an animal (provide Material Safety 















                        YES 
NO 
Handling of waste   
Fomites 
Body Excretions      
Trauma 
Aerosol                    
Other 
                        Handling of waste   








Body Excretions      
Trauma 
Aerosol                    
Other 
                        YES 
NO 
Handling of waste   
Fomites 
Body Excretions      
Trauma 
Aerosol                    
Other 
                        YES 
NO 
Handling of waste   
Fomites 
Body Excretions      
Trauma 
Aerosol                    
Other 
1.2  Will any innoculated organism from question 1.1 
remain viable in the animal model?  If no, attach 
documentation for each. 
YES NO 
If yes, how long will infection persist?        
1.3  Do infected animals require housing?  YES NO 
If Yes: 
Are cage/animal generated aerosols a 
concern?  
YES NO 
Do bedding and dirty caging pose a 
hazard?   
YES NO 
Do bites or scratches pose a hazard? 
  YES NO 
                      If YES, do you have a 
bite protocol? 
YES NO 
1.4  How are the infected material(s) to be 
treated prior to disposal? 
      
1.5  How are the carcasses to be disposed of?       
1.6  Other?       
 
Schedule 2 Hazard Assessment for Use of Recombinant DNA 
 No Recombinant DNA Use (Go to Schedule 3) 
  
2.1  Will proposed animal use involve genetically engineered YES NO 





organisms or cells containing engineered molecules? 
If YES, indicate what changes 
have been affected 
      
2.2 Is this expected to increase the invasiveness, toxicity or 
tumorigenicity of the agent in the animal? 
YES NO 
2.3 Describe steps taken to 
mitigate the risks. 
      
 
Schedule 3 Hazard Assessments for Work with Chemicals 
 No Chemical Use (Go to Schedule 4) 
3.1 Will potentially toxic chemicals be used with 
live animals? 
 YES NO Chemical Name: 
 
 
3.2 Will potentially carcinogenic chemicals be used 
with live animals? 
 YES NO Chemical Name: 
 
Please attach a Material Safety Data Sheet for any TOXIC or CARCINOGENIC chemical 
to be used in the protocol. 
3.3 How will the chemical(s) be administered 
into the animal? 
 
3.4 Will chemical or metabolite be excreted (faeces, urine, through skin, 
tears, sperm, etc.)? 
YES
  NO
3.5 State preventative measure that 
must be taken to minimize the risk of 
exposure for research staff. 
 
3.6 State preventative measure that 
must be taken to minimize the risk of 






Personnel working with these products directly or indirectly 
require the following training – 
















Schedule 4 Hazard Assessment and WHMIS Inventory for Work 
with Radioisotopes 
 No Radioisotope Use (Go to Schedule 5) 
4.1 Will radioisotopes be administered in live animals? If No, please 




1. Laboratory Location 
 
 




3. Dose to the animal   
 uCj/kg   
or  
kBg/kg 
4.2 Will the radioisotope-contaminated animal be returning alive for 




1. Identify the primary route of excretion for the radioisotope  
2. Animal quarters location Building    
Room # 
 
3. Duration of excretion  
4. Storage locations of animal 
carcass 
Building   
Room # 
 
If NO Storage locations of animal carcass Building  
Room # 
   
4.3 Internal Permit Holder Name  
Permit #  
 
4.4 State preventative measures that must be taken to minimize the risk of  



















    
Schedule 5 Hazard Assessment and WHMIS Inventory for Work 
with Radiation 
 No Radiation Use (Go to Schedule 6) 





1. Name(s) of personnel who will perform animal irradiation 
 
 















2. Location of X-ray machine Building   
Room  
 




If YES 1. Have personnel received specific training (MRI, CT scan)? YES
 






2. Specify type and location. Type  
 
 Building   Room  
 
5.4   Is the machine in a human space?    YES
 
NO 








If NO Please explain  
5.6 State preventative measures that must 







Personnel working with these products directly or indirectly 



















Schedule 6 Approvals -   Please Sign & Date Below 













    05/05/08 
Occupational Health and Safety Approval - Office Use Only 
Signature of OHS Officer                                            
Date  
                                                                                    
mm/dd/yy  
                                                                                       
/       
Institution (UWO, RRI, 
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